


WEST Search History

DATE: Thursday, November 18, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L23	L22 AND peptide	110
<input type="checkbox"/>	L22	L21 AND Fc receptor	113
<input type="checkbox"/>	L21	immunoglobulin heavy chain constant region	407
<input type="checkbox"/>	L20	L19 AND Fc receptor AND immunoglobulin	149
<input type="checkbox"/>	L19	514/2.CCLS.	6383
<input type="checkbox"/>	L18	L17 AND peptide	543
<input type="checkbox"/>	L17	L16 AND Fc receptor AND immunoglobulin	563
<input type="checkbox"/>	L16	435/7.1.CCLS.	9015
<input type="checkbox"/>	L15	L14 AND peptide	176
<input type="checkbox"/>	L14	L13 AND Fc receptor AND immunoglobulin	202
<input type="checkbox"/>	L13	424/130.1.CCLS.	1492
<input type="checkbox"/>	L12	Gosselin.IN.	633
<input type="checkbox"/>	L11	Gosselin-M.IN.	12
<input type="checkbox"/>	L10	Gosselin-Michael.IN.	2
<input type="checkbox"/>	L9	Joyal.IN.	37
<input type="checkbox"/>	L8	Joyal-J.IN.	0
<input type="checkbox"/>	L7	Joyal-John.IN.	0
<input type="checkbox"/>	L6	Israel.IN.	3948
<input type="checkbox"/>	L5	Israel-D.IN.	12
<input type="checkbox"/>	L4	Israel-David.IN.	14
<input type="checkbox"/>	L3	Gefter.IN.	214
<input type="checkbox"/>	L2	Gefter-M.IN.	5
<input type="checkbox"/>	L1	(Gefter-Malcolm.IN.)	4

END OF SEARCH HISTORY



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Fc receptor AND immunoglobulin heavy chain con Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 34 of 34

One page.

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

☐ 1: [Wagner B, Greiser-Wilke I, Wege AK, Radbruch A, Leibold W.](#) [Related Articles, Links](#)

Evolution of the six horse IGHG genes and corresponding immunoglobulin gamma heavy chains.
Immunogenetics. 2002 Aug;54(5):353-64. Epub 2002 Jul 04.
PMID: 12185539 [PubMed - indexed for MEDLINE]

☐ 2: [Reitan SK, Hannestad K.](#) [Related Articles, Links](#)

Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions.
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7588-93.
PMID: 12032327 [PubMed - indexed for MEDLINE]

☐ 3: [Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A.](#) [Related Articles, Links](#)

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Clin Immunol. 2001 Feb;98(2):164-74.
PMID: 11161972 [PubMed - indexed for MEDLINE]

☐ 4: [Kim MK, Pan XQ, Huang ZY, Hunter S, Hwang PH, Indik ZK, Schreiber AD.](#) [Related Articles, Links](#)

Fc gamma receptors differ in their structural requirements for interaction with the tyrosine kinase Syk in the initial steps of signaling for phagocytosis.
Clin Immunol. 2001 Jan;98(1):125-32.
PMID: 11141335 [PubMed - indexed for MEDLINE]

☐ 5: [Lima JO, Zhang L, Atkinson TP, Philips J, Dasanayake AP, Schroeder HW Jr.](#) [Related Articles, Links](#)





















Early expression of iepsilon, CD23 (FcepsilonRII), IL-4Ralpha, and IgE in the human fetus.
J Allergy Clin Immunol. 2000 Nov;106(5):911-7.
PMID: 11080714 [PubMed - indexed for MEDLINE]











☐ 6: [Pioli C, Gatta L, Ubaldi V, Doria G.](#) [Related Articles, Links](#)


Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor.
J Immunol. 2000 Nov 15;165(10):5530-6.
PMID: 11067906 [PubMed - indexed for MEDLINE]

☐ 7: [Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA.](#) [Related Articles, Links](#)

In vitro characterization of five humanized OKT3 effector function variant antibodies.
Cell Immunol. 2000 Feb 25;200(1):16-26.
PMID: 10716879 [PubMed - indexed for MEDLINE]


-  **8:** [Bhushan A, Barnhart B, Shone S, Song C, Covey LR.](#) [Related Articles](#), [Links](#)
 **A transcriptional defect underlies B lymphocyte dysfunction in a patient diagnosed with non-X-linked hyper-IgM syndrome.**
J Immunol. 2000 Mar 15;164(6):2871-80.
PMID: 10706672 [PubMed - indexed for MEDLINE]
-  **9:** [Park HJ, So EY, Lee CE.](#) [Related Articles](#), [Links](#)
 **Interferon-gamma-induced factor binding to the interleukin-4-responsive element of CD23b promoter in human tonsillar mononuclear cells: role in transient up-regulation of the interleukin-4-induced CD23b mRNA.**
Mol Immunol. 1998 Mar;35(4):239-47.
PMID: 9736340 [PubMed - indexed for MEDLINE]
-  **10:** [Cole MS, Anasetti C, Tso JY.](#) [Related Articles](#), [Links](#)
 **Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.**
J Immunol. 1997 Oct 1;159(7):3613-21.
PMID: 9317161 [PubMed - indexed for MEDLINE]
-  **11:** [Coloma MJ, Morrison SL.](#) [Related Articles](#), [Links](#)
 **Design and production of novel tetravalent bispecific antibodies.**
Nat Biotechnol. 1997 Feb;15(2):159-63.
PMID: 9035142 [PubMed - indexed for MEDLINE]
-  **12:** [Chen Y, Maguire T, Marks RM.](#) [Related Articles](#), [Links](#)
 **Demonstration of binding of dengue virus envelope protein to target cells.**
J Virol. 1996 Dec;70(12):8765-72.
PMID: 8971005 [PubMed - indexed for MEDLINE]
-  **13:** [Schuurman J, Lourens TE, Perdok GJ, Parren PW, Aalberse RC.](#) [Related Articles](#), [Links](#)
 **Mouse/human chimeric IgE antibodies directed to the house dust mite allergen Der p 2.**
Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):465-6. No abstract available.
PMID: 7613217 [PubMed - indexed for MEDLINE]
-  **14:** [Shin SU, Friden P, Moran M, Olson T, Kang YS, Pardridge WM, Morrison SL.](#) [Related Articles](#), [Links](#)
 **Transferrin-antibody fusion proteins are effective in brain targeting.**
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2820-4.
PMID: 7708731 [PubMed - indexed for MEDLINE]
-  **15:** [Michaelsen TE, Brekke OH, Aase A, Sandin RH, Bremnes B, Sandlie I.](#) [Related Articles](#), [Links](#)
 **One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge.**
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9243-7.
PMID: 7937748 [PubMed - indexed for MEDLINE]
-  **16:** [Wright A, Morrison SL.](#) [Related Articles](#), [Links](#)
 **Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.**
J Exp Med. 1994 Sep 1;180(3):1087-96.
PMID: 8064227 [PubMed - indexed for MEDLINE]
-  **17:** [Carayannopoulos L, Max EE, Capra JD.](#) [Related Articles](#), [Links](#)
 **Recombinant human IgA expressed in insect cells.**
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8348-52.
PMID: 8078886 [PubMed - indexed for MEDLINE]


-  **18:** [Amin AR, Tamma SM, Swenson CD, Kieda CC, Oppenheim JD, Finkelman FD, Coico RF.](#) [Related Articles, Links](#)
The immunoaugmenting properties of murine IgD reside in its C delta 1 and C delta 3 regions: potential role for IgD-associated glycans.
 Int Immunol. 1993 Jun;5(6):607-14.
 PMID: 8347555 [PubMed - indexed for MEDLINE]
-  **19:** [Shin SU, Wei CF, Amin AR, Thorbecke GJ, Morrison SL.](#) [Related Articles, Links](#)
Structural and functional properties of mouse-human chimeric IgD.
 Hum Antibodies Hybridomas. 1992 Apr;3(2):65-74.
 PMID: 1633267 [PubMed - indexed for MEDLINE]
-  **20:** [McMillan DR, Faust C.](#) [Related Articles, Links](#)
The expression and characterization of rat IgE produced by construction of the epsilon-heavy chain gene from exon modules.
 J Biol Chem. 1992 Mar 5;267(7):4904-10.
 PMID: 1537868 [PubMed - indexed for MEDLINE]
-  **21:** [Lund J, Pound JD, Jones PT, Duncan AR, Bentley T, Goodall M, Levine BA, Jefferis R, Winter G.](#) [Related Articles, Links](#)
Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma R11.
 Mol Immunol. 1992 Jan;29(1):53-9.
 PMID: 1530984 [PubMed - indexed for MEDLINE]
-  **22:** [Amin AR, Tamma SM, Oppenheim JD, Finkelman FD, Kieda C, Coico RF, Thorbecke GJ.](#) [Related Articles, Links](#)
Specificity of the murine IgD receptor on T cells is for N-linked glycans on IgD molecules.
 Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9238-42.
 PMID: 1924387 [PubMed - indexed for MEDLINE]
-  **23:** [Tamma SM, Amin AR, Finkelman FD, Chen YW, Thorbecke GJ, Coico RF.](#) [Related Articles, Links](#)
IgD receptors on murine T-helper cells bind to Fd and Fc regions of immunoglobulin D.
 Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9233-7.
 PMID: 1833776 [PubMed - indexed for MEDLINE]
-  **24:** [Gillies SD, Wesolowski JS.](#) [Related Articles, Links](#)
Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
 Hum Antibodies Hybridomas. 1990;1(1):47-54.
 PMID: 2129419 [PubMed - indexed for MEDLINE]
-  **25:** [Trautnecker A, Schneider J, Kiefer H, Karjalainen K.](#) [Related Articles, Links](#)
Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
 Nature. 1989 May 4;339(6219):68-70.
 PMID: 2541344 [PubMed - indexed for MEDLINE]
-  **26:** [Shaw DR, Khazaeli MB, LoBuglio AF.](#) [Related Articles, Links](#)
Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses.
 J Natl Cancer Inst. 1988 Dec 7;80(19):1553-9.
 PMID: 3143014 [PubMed - indexed for MEDLINE]
-  **27:** [Burton DR, Jefferis R, Partridge LJ, Woof JM.](#) [Related Articles, Links](#)

-  **Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI).**
Mol Immunol. 1988 Nov;25(11):1175-81.
PMID: 2975762 [PubMed - indexed for MEDLINE]


 **28:** [Mathur A, Lynch RG, Kohler G.](#)


[Related Articles, Links](#)

-  **Expression, distribution and specificity of Fc receptors for IgM on murine B cells.**
J Immunol. 1988 Sep 15;141(6):1855-62.
PMID: 2971716 [PubMed - indexed for MEDLINE]


 **29:** [Vojtiskova J, Franek F.](#)


[Related Articles, Links](#)

-  **The CH3 domain of pig immunoglobulin G. A study of structural heterogeneity and enzymic fragmentation.**
Folia Biol (Praha). 1986;32(5):311-24.
PMID: 3147201 [PubMed - indexed for MEDLINE]


 **30:** [Burton DR, Gregory L, Jefferis R.](#)


[Related Articles, Links](#)

-  **Aspects of the molecular structure of IgG subclasses.**
Monogr Allergy. 1986;19:7-35. No abstract available.
PMID: 2945094 [PubMed - indexed for MEDLINE]


 **31:** [Birshtein BK, Campbell R, Diamond B.](#)


[Related Articles, Links](#)

-  **Effects of immunoglobulin structure on Fc receptor binding: a mouse myeloma variant immunoglobulin with a gamma 2b-gamma 2a hybrid heavy chain having a complete gamma 2a Fc region fails to bind to gamma 2a Fc receptors on mouse macrophages.**
J Immunol. 1982 Aug;129(2):610-4.
PMID: 6806375 [PubMed - indexed for MEDLINE]


 **32:** [Ratcliffe A, Stanworth DR.](#)


[Related Articles, Links](#)

-  **The use of synthetic gamma-chain peptides in the localization of the binding site(s) on human IgG1 for the Fc receptors of homologous monocytes and heterologous mouse macrophages.**
Immunol Lett. 1982 Apr;4(4):215-21.
PMID: 6212539 [PubMed - indexed for MEDLINE]


 **33:** [Klein M, Haeffner-Cavaillon N, Isenman DE, Rivat C, Navia MA, Davies DR, Dorrington KJ.](#)





[Related Articles, Links](#)

-  **Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region.**
Proc Natl Acad Sci U S A. 1981 Jan;78(1):524-8.
PMID: 6787591 [PubMed - indexed for MEDLINE]

 **34:** [Johanson RA, Shaw AR, Schlamowitz M.](#)

[Related Articles, Links](#)

-  **Evidence that the CH2 domain of IgG contains the recognition unit for binding by the fetal rabbit yolk sac membrane receptor.**
J Immunol. 1981 Jan;126(1):194-9. No abstract available.
PMID: 6778915 [PubMed - indexed for MEDLINE]

Display **Summary**  **Show:** **500**  **Sort**  **Send to** **Text** 

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 16 2004 07:00:47

Connecting via winsock to STN

* * * * * welcome to STN International * * * * *
* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:34:17 ON 18 NOV 2004

=> File BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'ANABSTR' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:34:25 ON 18 NOV 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 16:34:25 ON 18 NOV 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'CAPLUS' ENTERED AT 16:34:25 ON 18 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:34:25 ON 18 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:34:25 ON 18 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Proquest Information and Learning company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'FOMAD' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'HEALSAFE' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:34:25 ON 18 NOV 2004

FILE 'NIOSHTIC' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:34:25 ON 18 NOV 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 16:34:25 ON 18 NOV 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 16:34:25 ON 18 NOV 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 16:34:25 ON 18 NOV 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Prous science

FILE 'PS' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 16:34:25 ON 18 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Prous science

FILE 'TOXCENTER' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 16:34:25 ON 18 NOV 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:34:25 ON 18 NOV 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 16:34:25 ON 18 NOV 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S Fc receptor
25 FILES SEARCHED...
52 FILES SEARCHED...
L1 70975 FC RECEPTOR

=> S immunoglobulin heavy chain constant region
19 FILES SEARCHED...
32 FILES SEARCHED...
53 FILES SEARCHED...
69 FILES SEARCHED...
L2 1459 IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION

=> S L1 AND L2
36 FILES SEARCHED...
L3 209 L1 AND L2

=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4 201 DUP REM L3 (8 DUPLICATES REMOVED)

=> D L4 1-201

L4 ANSWER 1 OF 201 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 1
AN 10494653 IFIPAT;IFIUDB;IFICDB
TI CHIMERIC ANTIGENS FOR ELICITING AN IMMUNE RESPONSE
IN George Rajan (CA); Noujaim Antoine (CA); Tyrrell Lorne (CA)
PA Unassigned Or Assigned To Individual (68000)
PI US 2004001853 A1 20040101
AI US 2003-365620 20030213
PRAI US 2002-390564P 20020620 (Provisional)
US 2002-423578P 20021105 (Provisional)
FI US 2004001853 20040101
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
OS CA 140:75948
CLMN 39
GI 61 Figure(s).

FIG. 1 is a schematic diagram illustrating the structure of the chimeric antigen of the present invention as a monomer, wherein the chimeric antigen has two portions, namely a viral antigen and a xenotypic murine Fc fragment with the hinge region present.

FIG. 1a is a schematic diagram illustrating the structure of the chimeric antigen of FIG. 1 in its normal, assembled state as a dimer.

FIG. 2 is a schematic diagram illustrating the structure of a modified chimeric antigen as a monomer, wherein the chimeric antigen has two portions, namely a modified viral antigen portion which incorporates in the Complementarity Determining Regions (CDR) any viral antigen or antigens, antigenic protein fragments or peptides, or any of these with glycosylation at specific sites, and a xenotypic binding agent, namely a murine Fc fragment with the hinge region present.

FIG. 2a is a schematic diagram illustrating the structure of the modified chimeric antigen of FIG. 2 in its normal, assembled state as a dimer. The abbreviations "Ag1," "Ag2," and "Ag3" represent different viral antigenic peptides or proteins.

FIG. 3 is a schematic diagram illustrating the structure of a modified biotinylated viral protein and a fusion protein of a streptavidin-Fc fragment with the hinge region present.

FIG. 3a is a schematic diagram illustrating the structure of the modified chimeric antigen of FIG. 3 in its normal, assembled state as a dimer.

FIG. 4 is a schematic diagram illustrating a recombinant bacmid.

FIG. 5 is a schematic embodiment of TBD of the present invention.

FIG. 6 shows the nucleotide sequences of the open reading frame encoding the TBD of FIG. 5.

FIG. 7 is a schematic embodiment of an exemplary chimeric antigen of the present invention, suitable for use with an insect cell expression

system.

FIG. 8 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 7.

FIG. 9 shows the nucleotide and deduced amino acid sequences of the expressed HBV S1/S2 protein.

FIG. 10 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 11 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 10.

FIG. 12 shows the nucleotide and deduced amino acid sequences of the expressed HBV S1/S2/S protein.

FIG. 13 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 14 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 13.

FIG. 15 shows the nucleotide and deduced amino acid sequences of the expressed HBV core protein.

FIG. 16 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 17 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 16.

FIG. 18 shows the nucleotide and deduced amino acid sequences of the expressed DHBV Pres protein.

FIG. 19 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 20 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 19.

FIG. 21 shows the nucleotide and deduced amino acid sequences of the expressed DHBV Pres/S protein.

FIG. 22 is a schematic embodiment of an exemplary chimeric antigen of the present invention, illustrating an exemplary IRD of the present invention.

FIG. 23 shows the nucleotide and deduced amino acid sequences of the chimeric antigen molecule of FIG. 22.

FIG. 24 shows the nucleotide and deduced amino acid sequences of the expressed DHBV core protein.

FIG. 25 shows that a chimeric antigen embodiment of the invention can be taken up by dendritic cells.

FIG. 26 shows that dendritic cells uptake a chimeric antigen of the present invention (CS12), as compared to the target binding domain (TBD) alone, or the immune response domain (IRD) alone.

FIG. 27 shows the expression of MHC Class II by dendritic cells.

FIG. 28 shows that a cellular response is generated after contact with dendritic cells activated with a chimeric antigen of the present invention.

FIG. 29 shows T cell stimulation by a chemical conjugate of the present invention.

FIG. 30 shows the time course of expression of antigen binding receptors on maturing dendritic cells.

FIG. 31 shows the time course of expression of various dendritic cells activation markers.

FIG. 32 shows the nucleotide (A) and amino acid (B) sequences of the ORF of TBD protein in the plasmid pFastbachta-tbd.

FIG. 33 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HBV S1/S2-TBD in the plasmid pFastbachta-tbd.

FIG. 34 shows the comparison of binding of HBV S1/S2-TBD, IgG1, and IgG2 over time.

FIG. 35 shows the comparison of HBV S1/S2-TBD, IgG1, and IgG2a binding to maturing dendritic cells on day 1.

FIG. 36 shows the comparison of HBV S1/S2-TBD, IgG1, and IgG2a binding to maturing dendritic cells on day 4.

FIG. 37 shows the comparison of uptake between HBV S1/S2-TBD, IgG1, and IgG2 as a function of concentration.

FIG. 38 shows the correlation of HBV S1/S2-TBD to CD32 and CD206 expression on dendritic cells.

FIG. 39 shows that the binding of HBV S1/S2-TBD to DC32 and DC206 receptors on dendritic cells is abolished by anti-Fc Mab.

FIG. 40 shows that glycosylation of S1/S2 antigen increases the uptake via the CD206 receptor.

FIG. 41 shows intracellular interferon-gamma positive T cells after antigen presentation.

FIG. 42 shows secretion of interferon-gamma after antigen presentation.

FIG. 43 shows intracellular interferon-gamma positive cells as a function of S1/S2-TBD concentration
 FIG. 44 shows interferon-gamma secretion by T cells as a function of S1/S2-TBD concentration.
 FIG. 45 shows the effect of glycosylation on intracellular interferon-gamma production in T cells.
 FIG. 46 shows the effect of glycosylation on interferon-gamma secretion by T cells.
 FIG. 47 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV Core in the plasmid pFastbachta-HCV.
 FIG. 48 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV Core in the plasmid pFastbachta-HCV-TBD.
 FIG. 49 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV Core in the plasmid pFastbachta-HCV-core.
 FIG. 50 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV Core-TBD protein in the plasmid pFastbachta-HCVcore-TBD.
 FIG. 52 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV NS5A in the plasmid pFastbachta-HCV-NS5A.
 FIG. 52 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV NS5A-TBD in the plasmid pFastbachta-HCV-NS5A-TBD
 FIG. 53 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E1 in the plasmid pFastbachta-HCV-E1.
 FIG. 54 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E1-TBD in the plasmid pFastbachta-HCV-E1-TBD.
 FIG. 55 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E2 in the plasmid pFastbachta-HCV-E2.
 FIG. 56 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E2-TBD in the plasmid pFastbachta-HCV-E2-TBD.
 FIG. 57 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E1/E2 in the plasmid pFastbachta-HCV-E1/E2.
 FIG. 58 shows the nucleotide (A) and amino acid (B) sequences of the ORF of HCV E1/E2-TBD in the plasmid pFastbachta-HCV-E1/E2TBD.

L4 ANSWER 2 OF 201 USPATFULL on STN
 AN 2004:273303 USPATFULL
 TI Antibodies against PD-1 and uses therefor
 IN Collins, Mary, Natick, MA, UNITED STATES
 Wood, Clive R., Boston, MA, UNITED STATES
 Carreno, Beatriz M., Acton, MA, UNITED STATES
 Luxenberg, Deborah, Melrose, MA, UNITED STATES
 Jussif, Jason, Salem, NH, UNITED STATES
 Carter, Laura L., Medford, MA, UNITED STATES
 Bennett, Frances K., Sudbury, MA, UNITED STATES
 Valge-Archer, Vivia, Little Abington, UNITED KINGDOM
 Andrews, John, Little Hadham Ware, UNITED KINGDOM
 Russell, Caroline, Royston, UNITED KINGDOM
 PA Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)
 Cambridge Antibody Technology, Cambridge, UNITED KINGDOM (U.S. corporation)
 PI US 2004213795 A1 20041028
 AI US 2003-741481 A1 20031222 (10)
 PRAI US 2002-435354P 20021223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2114
 INCL INCLM: 424/155.100
 INCL INCLS: 530/388.800
 NCL NCLM: 424/155.100
 NCL NCLS: 530/388.800
 IC [7]
 ICM: A61K039-395
 ICS: C07K016-30
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 201 USPATFULL on STN
 AN 2004:260603 USPATFULL
 TI Immunocytokine sequences and uses thereof
 IN Gillies, Stephen D., Carlisle, MA, UNITED STATES
 Lo, Kin-Ming, Lexington, MA, UNITED STATES
 PA EMD Lexigen Research Center Corp., Billerica, MA, UNITED STATES (U.S. corporation)
 PI US 2004203100 A1 20041014
 AI US 2003-737208 A1 20031216 (10)
 PRAI US 2002-433945P 20021217 (60)
 DT Utility
 FS APPLICATION

LN.CNT 1267
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/326.000; 530/387.100; 536/023.530
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/326.000; 530/387.100; 536/023.530
IC [7]
ICM: C07K016-18
ICS: C07H021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 201 USPATFULL on STN
AN 2004:203409 USPATFULL
TI Glycoprotein vi fusion proteins
IN Burger, Christa, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Gleitz, Johannes, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
Frech, Mathias, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
PI US 2004157300 A1 20040812
AI US 2004-483810 A1 20040115 (10)
WO 2002-EP7796 20020712
PRAI EP 2001-116717 20010718
DT Utility
FS APPLICATION
LN.CNT 1202
INCL INCLM: 435/069.700
INCLS: 435/320.100; 435/328.000; 530/391.100
NCL NCLM: 435/069.700
NCLS: 435/320.100; 435/328.000; 530/391.100
IC [7]
ICM: C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 201 USPATFULL on STN
AN 2004:177822 USPATFULL
TI Methods and compositions comprising glycoprotein glycoforms
IN Raju, T. Shantha, San Mateo, CA, UNITED STATES
PA Genentech, Inc., South San Francisco, CA (U.S. corporation)
PI US 2004136986 A1 20040715
AI US 2003-744844 A1 20031223 (10)
RLI Continuation of Ser. No. US 1998-183824, filed on 30 Oct 1998, ABANDONED
PRAI US 1997-63871P 19971031 (60)
DT Utility
FS APPLICATION
LN.CNT 1909
INCL INCLM: 424/144.100
NCL NCLM: 424/144.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 201 USPATFULL on STN
AN 2004:158160 USPATFULL
TI Use of A33 antigens JAM-it
IN Ashkenazi, Avi, San Mateo, CA, UNITED STATES
Fong, Sherman, Alameda, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Napier, Mary A., Hillsborough, CA, UNITED STATES
Tumas, Daniel, Orinda, CA, UNITED STATES
Lookeren, Menno Van, San Francisco, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
PI US 2004120957 A1 20040624
AI US 2003-633008 A1 20030731 (10)
RLI Continuation-in-part of Ser. No. US 2002-265542, filed on 3 Oct 2002,
PENDING Continuation-in-part of Ser. No. WO 2000-US4414, filed on 22 Feb
2000, PENDING Continuation-in-part of Ser. No. WO 2000-US14042, filed on
22 May 2000, PENDING Continuation-in-part of Ser. No. WO 2000-US32678,
filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US
1999-254465, filed on 5 Mar 1999, GRANTED, Pat. No. US 6410708
Continuation-in-part of Ser. No. WO 1999-US5028, filed on 8 Mar 1999,
PENDING Continuation-in-part of Ser. No. US 1999-380138, filed on 25 Aug
1999, ABANDONED Continuation-in-part of Ser. No. US 1999-380139, filed
on 25 Aug 1999, ABANDONED Continuation-in-part of Ser. No. WO
1998-US19330, filed on 16 Sep 1998, PENDING Continuation-in-part of Ser.
No. US 2001-953499, filed on 14 Sep 2001, PENDING Continuation of Ser.
No. WO 1998-US24855, filed on 20 Nov 1998, PENDING
DT Utility

FS APPLICATION
LN.CNT 6476
INCL INCLM: 424/146.100
NCL NCLM: 424/146.100
IC [7]
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 201 USPATFULL on STN
AN 2004:152111 USPATFULL
TI Modulators of P-selectin glycoprotein ligand 1
IN Lin, Rong-Hwa, Taipei, TAIWAN, PROVINCE OF CHINA
Chang, Chung Nan, Foster City, CA, UNITED STATES
PI US 2004116333 A1 20040617
AI US 2003-662906 A1 20030915 (10)
RLI Continuation-in-part of Ser. No. US 2002-51497, filed on 18 Jan 2002,
PENDING
PRAI US 2001-310196P 20010803 (60)
DT Utility
FS APPLICATION
LN.CNT 1607
INCL INCLM: 514/008.000
NCL NCLM: 514/008.000
IC [7]
ICM: A61K038-17
ICS: A61K038-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 201 USPATFULL on STN
AN 2004:145259 USPATFULL
TI Cytokine zalphall ligand
IN Novak, Julia E., Bainbridge Island, WA, UNITED STATES
Presnell, Scott R., Tacoma, WA, UNITED STATES
Sprecher, Cindy A., Seattle, WA, UNITED STATES
Foster, Donald C., Lake Forest Park, WA, UNITED STATES
Holly, Richard D., Seattle, WA, UNITED STATES
Gross, Jane A., Seattle, WA, UNITED STATES
Johnston, Janet V., Seattle, WA, UNITED STATES
Nelson, Andrew J., Shoreline, WA, UNITED STATES
Dillon, Stacey R., Seattle, WA, UNITED STATES
Hammond, Angela K., Maple Valley, WA, UNITED STATES
PA ZymoGenetics, Inc. (U.S. corporation)
PI US 2004110932 A1 20040610
AI US 2003-659684 A1 20030910 (10)
RLI Continuation of Ser. No. US 2000-522217, filed on 9 Mar 2000, GRANTED,
Pat. No. US 6307024
PRAI US 1999-123547P 19990309 (60)
US 1999-123904P 19990311 (60)
US 1999-142013P 19990701 (60)
DT Utility
FS APPLICATION
LN.CNT 8687
INCL INCLM: 530/388.220
INCLS: 424/143.100
NCL NCLM: 530/388.220
NCLS: 424/143.100
IC [7]
ICM: A61K039-395
ICS: C07K016-28

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 201 USPATFULL on STN
AN 2004:107639 USPATFULL
TI Artificial proteins with reduced immunogenicity
IN Gillies, Stephen, Carlisle, MA, UNITED STATES
Carr, Francis J, Balmedie, UNITED KINGDOM
Tim, Jones, Babraham, UNITED KINGDOM
Carter, Graham, By Newmachar, UNITED KINGDOM
Hamilton, Anita, Aberdeen, UNITED KINGDOM
Williams, Stephen, Auchleven, Inch, UNITED KINGDOM
Hanlon, Marian, Cambridge, UNITED KINGDOM
Watkins, John P, Girton, UNITED KINGDOM
Baker, Matthew, Littleport, Ely, UNITED KINGDOM
Way, Jeffrey C, Cambridge, UNITED KINGDOM
PI US 2004082039 A1 20040429
AI US 2003-468370 A1 20030819 (10)

WO 2002-EP1690 20020218
PRAI EP 2001-103955 20010219
EP 2001-108291 20010405
DT Utility
FS APPLICATION
LN.CNT 6991
INCL INCLM: 435/069.700
INCLS: 424/185.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.700
NCLS: 424/185.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07H021-04
ICS: C12P021-04; A61K039-00; C07K014-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 201 USPATFULL on STN
AN 2004:101671 USPATFULL
TI Compositions and methods for modulating physiology of epithelial
junctional adhesion molecules for enhanced mucosal delivery of
therapeutic compounds
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004077540 A1 20040422
AI US 2003-601953 A1 20030624 (10)
PRAI US 2002-392512P 20020628 (60)
DT Utility
FS APPLICATION
LN.CNT 13170
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]
ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 201 USPATFULL on STN
AN 2004:94846 USPATFULL
TI Multiple cytokine protein complexes
IN Gillies, Stephen D., Carlisle, MA, UNITED STATES
Lo, Kin-Ming, Lexington, MA, UNITED STATES
PI US 2004072299 A1 20040415
AI US 2003-603064 A1 20030624 (10)
RLI Continuation of Ser. No. US 2000-634368, filed on 9 Aug 2000, GRANTED,
Pat. No. US 6617135
PRAI US 1999-147924P 19990809 (60)
DT Utility
FS APPLICATION
LN.CNT 2752
INCL INCLM: 435/069.500
INCLS: 435/320.100; 435/325.000; 530/351.000; 530/391.100; 536/023.530
NCL NCLM: 435/069.500
NCLS: 435/320.100; 435/325.000; 530/351.000; 530/391.100; 536/023.530
IC [7]
ICM: C07K016-46
ICS: C07K014-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 201 USPATFULL on STN
AN 2004:89782 USPATFULL
TI Transgenic ungulates capable of human antibody production
IN Robl, James M., Brandon, SD, UNITED STATES
Collas, Philippe, Oslo, NORWAY
Sullivan, Eddie, Manhattan, KS, UNITED STATES
Kasinathan, P., Manhattan, KS, UNITED STATES
Goldsby, Richard A., Leverett, MA, UNITED STATES
Kuroiwa, Yoshimi, Sionx Falls, JAPAN
Tomizuka, Kazuma, Takasaki, JAPAN
Ishida, Isao, Isehara, JAPAN
PI US 2004068760 A1 20040408
AI US 2003-441503 A1 20030519 (10)
RLI Continuation-in-part of Ser. No. US 2001-988115, filed on 16 Nov 2001,
PENDING Continuation-in-part of ser. No. US 2000-714185, filed on 17 Nov
2000, PENDING Continuation-in-part of ser. No. US 2001-32191, filed on
21 Dec 2001, PENDING
PRAI US 2002-381531P 20020517 (60)
US 2002-425056P 20021108 (60)
US 2001-311625P 20010809 (60)

US 2000-256458P 20001220 (60)
US 1999-166410P 19991119 (60)
US 2000-258151P 20001222 (60)
DT Utility
FS APPLICATION
LN.CNT 8417
INCL INCLM: 800/006.000
INCLS: 800/014.000; 800/015.000; 800/016.000; 800/017.000
NCL NCLM: 800/006.000
NCLS: 800/014.000; 800/015.000; 800/016.000; 800/017.000
IC [7]
ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 201 USPATFULL on STN
AN 2004:82681 USPATFULL
TI UMLR polypeptides
IN Xu, Wenfeng, Mukilteo, WA, UNITED STATES
Lofton-Day, Catherine E., Brier, WA, UNITED STATES
Henne, Randal M., Seattle, WA, UNITED STATES
Presnell, Scott R., Tacoma, WA, UNITED STATES
Yao, Yue, Kenmore, WA, UNITED STATES
Novak, Julia E., Bainbridge Island, WA, UNITED STATES
PA ZymoGenetics, Inc. (U.S. corporation)
PI US 2004063132 A1 20040401
AI US 2003-660968 A1 20030912 (10)
RLI Continuation of Ser. No. US 2000-695369, filed on 23 Oct 2000, ABANDONED
PRAI US 1999-160880P 19991022 (60)
US 1999-163215P 19991102 (60)
US 2000-218769P 20000717 (60)
US 2000-222221P 20000801 (60)
DT Utility
FS APPLICATION
LN.CNT 5048
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220;
536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.220;
536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-715; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 201 USPATFULL on STN
AN 2004:70139 USPATFULL
TI Expression and export of anti-obesity proteins as Fc fusion proteins
IN Lo, Kin-Ming, Lexington, MA, UNITED STATES
Zhang, Jinyang, Arlington, MA, UNITED STATES
Gillies, Stephen D., Carlisle, MA, UNITED STATES
PA Lexigen Pharmaceuticals Corp., Lexington, MA, UNITED STATES (U.S. corporation)
PI US 2004053366 A1 20040318
AI US 2003-419058 A1 20030418 (10)
RLI Continuation of Ser. No. US 2000-479508, filed on 7 Jan 2000, ABANDONED
PRAI US 1999-115079P 19990107 (60)
DT Utility
FS APPLICATION
LN.CNT 1851
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/326.000; 530/387.100; 536/023.530
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/326.000; 530/387.100; 536/023.530
IC [7]
ICM: C12P021-02
ICS: C12P021-06; C07H021-04; C12N005-06; C07K016-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 201 USPATFULL on STN
AN 2004:69559 USPATFULL
TI ErbB4 antagonists
IN Gerritsen, Mary E, San Mateo, CA, UNITED STATES
Sliwowski, Mark X., San Carlos, CA, UNITED STATES
PI US 2004052786 A1 20040318
AI US 2003-362380 A1 20030806 (10)

WO 2001-US26984 20010829
DT Utility
FS APPLICATION
LN.CNT 3313
INCL INCLM: 424/143.100
NCL NCLM: 424/143.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 201 USPATFULL on STN
AN 2004:63731 USPATFULL
TI Novel nucleic acids and secreted polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Yang, Yonghong, San Jose, CA, UNITED STATES
Weng, Gezhi, Piedmont, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Ren, Feiyan, Cupertino, CA, UNITED STATES
Xue, Aidong, Sunnyvale, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Wehrman, Tom, Stanford, CA, UNITED STATES
Ghosh, Malabika J., Sunnyvale, CA, UNITED STATES
Wang, Dunrui, Poway, CA, UNITED STATES
Zhao, Qing A., San Jose, CA, UNITED STATES
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
PI US 2004048249 A1 20040311
AI US 2002-112944 A1 20020328 (10)
RLI Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000,
PENDING Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan
2000, ABANDONED Continuation-in-part of Ser. No. US 2000-496914, filed
on 3 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US
2000-515126, filed on 28 Feb 2000, ABANDONED Continuation-in-part of
Ser. No. US 2000-519705, filed on 7 Mar 2000, ABANDONED
Continuation-in-part of Ser. No. US 2000-540217, filed on 31 Mar 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-552929, filed on 18
Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-577408,
filed on 18 May 2000, ABANDONED
PRAI US 2001-306971P 20010721 (60)
DT Utility
FS APPLICATION
LN.CNT 23809
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000;
530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000;
530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47;
C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 201 USPATFULL on STN
AN 2004:58174 USPATFULL
TI Novel nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Asundi, Vinod, Foster City, CA, UNITED STATES
Wehrman, Tom, Stanford, CA, UNITED STATES
Ren, Feiyan, Cupertino, CA, UNITED STATES
Zhou, Ping, Cupertino, CA, UNITED STATES
Zhao, Qing A., San Jose, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Xue, Aidong, Sunnyvale, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Wang, Dunrui, Poway, CA, UNITED STATES
PI US 2004044181 A1 20040304
AI US 2003-363616 A1 20030715 (10)
WO 2001-US27093 20010831
DT Utility
FS APPLICATION
LN.CNT 17667
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500

NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 201 USPATFULL on STN
AN 2004:57455 USPATFULL
TI Bifunctional fusion proteins with glucocerebrosidase activity
IN Schumacher, silke, Heidelberg, GERMANY, FEDERAL REPUBLIC OF
Gillies, Stephen, Carlisle, MA, UNITED STATES
PI US 2004043457 A1 20040304
AI US 2003-466593 A1 20030717 (10)
WO 2001-EP15328 20011227
PRAI EP 2001-101056 20010118
DT Utility
FS APPLICATION
LN.CNT 931
INCL INCLM: 435/069.700
INCLS: 530/391.100; 435/326.000; 435/320.100
NCL NCLM: 435/069.700
NCLS: 530/391.100; 435/326.000; 435/320.100
IC [7]
ICM: C12P021-04
ICS: C07K016-46; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 201 USPATFULL on STN
AN 2004:50383 USPATFULL
TI Compositions and methods for enhanced mucosal delivery of interferon
beta
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Gupta, Malini, Dix Hills, NY, UNITED STATES
de Meireles, Jorge C., Syosset, NY, UNITED STATES
Abd El-Shafy, Mohammed, Hauppauge, NY, UNITED STATES
PA Natestch Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004037809 A1 20040226
AI US 2003-462452 A1 20030616 (10)
PRAI US 2002-393066P 20020628 (60)
DT Utility
FS APPLICATION
LN.CNT 10725
INCL INCLM: 424/085.600
NCL NCLM: 424/085.600
IC [7]
ICM: A61K038-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 201 USPATFULL on STN
AN 2004:44569 USPATFULL
TI Immunoglobulin DNA cassette molecules, monobody constructs, methods of
production, and methods of use therefor
IN O'Keefe, Theresa L., Waltham, MA, UNITED STATES
Healey, Judith Jacques, Newton, MA, UNITED STATES
Newman, Walter, Boston, MA, UNITED STATES
Ponath, Paul D., San Francisco, CA, UNITED STATES
Keyt, Bruce A., Hillsborough, CA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004033561 A1 20040219
AI US 2002-272899 A1 20021017 (10)
PRAI US 2001-350166P 20011019 (60)
US 2002-392364P 20020626 (60)
DT Utility
FS APPLICATION
LN.CNT 4267
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/326.000; 530/388.100; 536/023.530
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/326.000; 530/388.100; 536/023.530
IC [7]
ICM: C07H021-04
ICS: C12P021-02; C12N005-06; C07K016-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 201 USPATFULL on STN

AN 2004:38689 USPATFULL
TI Cytokine receptor
IN Presnell, Scott R., Tacoma, WA, UNITED STATES
Xu, Wenfeng, Seattle, WA, UNITED STATES
Novak, Julia E., Suquamish, WA, UNITED STATES
Whitmore, Theodore E., Redmond, WA, UNITED STATES
Grant, Francis J., Seattle, WA, UNITED STATES
Kindsvogel, Wayne R., Seattle, WA, UNITED STATES
Klucher, Kevin M., Bellevue, WA, UNITED STATES
PI US 2004029228 A1 20040212
AI US 2003-420034 A1 20030418 (10)
PRAI US 2002-373813P 20020419 (60)
DT Utility
FS APPLICATION
LN.CNT 6929
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 201 USPATFULL on STN
AN 2004:38077 USPATFULL
TI Dopamine agonist formulations for enhanced central nervous system delivery
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PA Natestch Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)
PI US 2004028613 A1 20040212
AI US 2001-891630 A1 20010625 (9)
DT Utility
FS APPLICATION
LN.CNT 8045
INCL INCLM: 424/045.000
INCLS: 514/295.000
NCL NCLM: 424/045.000
NCLS: 514/295.000
IC [7]
ICM: A61K031-473
ICS: A61L009-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 201 USPATFULL on STN
AN 2004:4396 USPATFULL
TI Muscle cells and their use in cardiac repair
IN Edge, Albert, Cambridge, MA, United States
PA Diacrin, Inc., Charlestown, MA, United states (U.S. corporation)
PI US 6673604 B1 20040106
AI US 2000-624885 20000724 (9)
PRAI US 1999-145849P 19990723 (60)
DT Utility
FS GRANTED
LN.CNT 2127
INCL INCLM: 435/347.000
INCLS: 435/325.000; 435/371.000
NCL NCLM: 435/347.000
NCLS: 435/325.000; 435/371.000
IC [7]
ICM: C12N005-06
ICS: C12N005-08
EXF 435/325; 435/347; 435/371; 424/93.21

L4 ANSWER 24 OF 201 USPATFULL on STN DUPLICATE 2
AN 2003:181690 USPATFULL
TI Novel cytokine zalpha11 ligand
IN Novak, Julia E., Bainbridge Island, WA, UNITED STATES
Presnell, Scott R., Tacoma, WA, UNITED STATES
Sprecher, Cindy A., Seattle, WA, UNITED STATES
Foster, Donald C., Lake Forest Park, WA, UNITED STATES
Holly, Richard D., Seattle, WA, UNITED STATES
Gross, Jane A., Seattle, WA, UNITED STATES
Johnston, Janet V., Seattle, WA, UNITED STATES
Nelson, Andrew J., Shoreline, WA, UNITED STATES
Dillon, Stacey R., Seattle, WA, UNITED STATES

Hammond, Angela K., Maple Valley, WA, UNITED STATES
PA ZymoGenetics, Inc. (U.S. corporation)
PI US 2003125524 A1 20030703
US 6686178 B2 20040203
AI US 2002-295723 A1 20021115 (10)
RLI Division of Ser. No. US 2000-522217, filed on 9 Mar 2000, GRANTED, Pat.
No. US 6307024
DT Utility
FS APPLICATION
LN.CNT 8817
INCL INCLM: 530/351.000
INCLS: 435/069.500; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 435/069.520
NCLS: 424/130.100; 424/143.100; 435/069.100; 435/070.100; 435/320.100;
435/325.000; 536/023.100; 536/024.100
IC [7]
ICM: C07K014-52
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 201 USPATFULL on STN
AN 2003:295758 USPATFULL
TI Transgenic animals for producing specific isotypes of human antibodies
via non-cognate switch regions
IN Green, Larry L., San Francisco, CA, UNITED STATES
Ivanov, Vladimir E., Fremont, CA, UNITED STATES
Davis, C. Geoffrey, Burlingame, CA, UNITED STATES
PA Abgenix, Inc. (U.S. corporation)
PI US 2003208781 A1 20031106
AI US 2003-349706 A1 20030121 (10)
RLI Continuation of Ser. No. US 1999-329582, filed on 10 Jun 1999, PENDING
DT Utility
FS APPLICATION
LN.CNT 3588
INCL INCLM: 800/006.000
INCLS: 800/018.000; 435/354.000; 536/023.530
NCL NCLM: 800/006.000
NCLS: 800/018.000; 435/354.000; 536/023.530
IC [7]
ICM: A01K067-027
ICS: C07H021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 201 USPATFULL on STN
AN 2003:283079 USPATFULL
TI ICAM-related protein
IN Gallatin, W. Michael, Mercer Island, WA, UNITED STATES
Vazeux, Rosemay, Seattle, WA, UNITED STATES
PI US 2003199423 A1 20031023
AI US 2002-163942 A1 20020605 (10)
RLI Continuation of Ser. No. US 2001-753436, filed on 3 Jan 2001, ABANDONED
Continuation of Ser. No. US 1999-382289, filed on 24 Aug 1999, ABANDONED
Continuation-in-part of Ser. No. US 1995-487113, filed on 7 Jun 1995,
GRANTED, Pat. No. US 5837822 Continuation-in-part of Ser. No. US
1993-102852, filed on 5 Aug 1993, ABANDONED Continuation-in-part of Ser.
No. US 1993-9266, filed on 22 Jan 1993, ABANDONED Continuation-in-part
of Ser. No. WO 1993-US787, filed on 26 Jan 1993, PENDING
Continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,
ABANDONED Continuation-in-part of Ser. No. US 1992-889724, filed on 26
May 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-827689,
filed on 27 Jan 1992, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 7097
INCL INCLM: 514/001.000
INCLS: 530/388.260; 435/007.900; 435/338.000
NCL NCLM: 514/001.000
NCLS: 530/388.260; 435/007.900; 435/338.000
IC [7]
ICM: A61K031-00
ICS: G01N033-53; G01N033-542; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 201 USPATFULL on STN
AN 2003:271148 USPATFULL
TI Directed switch-mediated DNA recombination

IN Jakobovits, Aya, Menlo Park, CA, UNITED STATES
Gallo, Michael Lajos, San Jose, CA, UNITED STATES
Yang, Xiao-Ping, Foster City, CA, UNITED STATES
PI US 2003190751 A1 20031009
AI US 2002-115668 A1 20020403 (10)
RLI Continuation of Ser. No. US 1999-369635, filed on 6 Aug 1999, GRANTED,
Pat. No. US 6395515 Continuation of Ser. No. US 1997-878166, filed on 17
Jun 1997, GRANTED, Pat. No. US 5985615 Continuation of Ser. No. US
1996-619109, filed on 20 Mar 1996, GRANTED, Pat. No. US 5714352
DT Utility
FS APPLICATION
LN.CNT 1423
INCL INCLM: 435/455.000
INCLS: 435/069.100; 435/320.100; 435/326.000
NCL NCLM: 435/455.000
NCLS: 435/069.100; 435/320.100; 435/326.000
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 201 USPATFULL on STN
AN 2003:257784 USPATFULL
TI In vitro modification of glycosylation patterns of recombinant
glycopeptides
IN Bayer, Robert J., San Diego, CA, UNITED STATES
PA Neose Technologies, Inc., Horsham, PA (U.S. corporation)
PI US 2003180835 A1 20030925
AI US 2003-391035 A1 20030317 (10)
RLI Continuation of Ser. No. US 2001-855320, filed on 14 May 2001, PENDING
PRAI US 2000-203851P 20000512 (60)
DT Utility
FS APPLICATION
LN.CNT 2077
INCL INCLM: 435/068.100
INCLS: 530/395.000; 435/193.000
NCL NCLM: 435/068.100
NCLS: 530/395.000; 435/193.000
IC [7]
ICM: C12P021-06
ICS: C12N009-10; C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 201 USPATFULL on STN
AN 2003:250484 USPATFULL
TI Humanized antibodies to human gp39, compositions containing and
therapeutic use thereof
IN Black, Amelia, Cardiff, CA, UNITED STATES
Hanna, Nabil, Olivenhian, CA, UNITED STATES
Padlan, Eduardo A., Kensington, MD, UNITED STATES
Newman, Roland L., San Diego, CA, UNITED STATES
PA IDEC PHARMACEUTICALS CORPORATION (U.S. corporation)
PI US 2003175269 A1 20030918
AI US 2002-171680 A1 20020617 (10)
RLI Continuation of Ser. No. US 1999-332595, filed on 14 Jun 1999, GRANTED,
Pat. No. US 6506383
DT Utility
FS APPLICATION
LN.CNT 2229
INCL INCLM: 424/141.100
INCLS: 530/388.150; 435/007.210
NCL NCLM: 424/141.100
NCLS: 530/388.150; 435/007.210
IC [7]
ICM: A61K039-395
ICS: C07K016-44; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 201 USPATFULL on STN
AN 2003:245990 USPATFULL
TI Method of producing single chain protein in plant cells
IN Hein, Mich B., Fallbrook, CA, UNITED STATES
Hiatt, Andrew, San Diego, CA, UNITED STATES
PA The Scripps Research Institute (U.S. corporation)
PI US 2003172407 A1 20030911
AI US 2003-374603 A1 20030227 (10)

RLI Continuation of Ser. No. US 1998-200657, filed on 25 Nov 1998, PENDING
Continuation of Ser. No. US 1996-642406, filed on 3 May 1996, GRANTED,
Pat. No. US 5959177 Continuation-in-part of Ser. No. US 1992-971951,
filed on 5 Nov 1992, GRANTED, Pat. No. US 5639947 Continuation of Ser.
No. US 1990-591823, filed on 2 Oct 1990, GRANTED, Pat. No. US 5202422
Continuation-in-part of Ser. No. US 1989-427765, filed on 27 Oct 1989,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4699
INCL INCLM: 800/288.000
INCLS: 530/387.100
NCL NCLM: 800/288.000
NCLS: 530/387.100
IC [7]
ICM: A01H001-00
ICS: C12N015-82; C07K016-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 201 USPATFULL on STN
AN 2003:244866 USPATFULL
TI Compositions and methods for modulation of immune responses
IN Soderstrom, Karl Petter, San Francisco, CA, UNITED STATES
PI US 2003171280 A1 20030911
AI US 2002-210148 A1 20020731 (10)
PRAI US 2001-308598P 20010731 (60)
DT Utility
FS APPLICATION
LN.CNT 4601
INCL INCLM: 514/012.000
INCLS: 530/327.000
NCL NCLM: 514/012.000
NCLS: 530/327.000
IC [7]
ICM: A61K038-17
ICS: C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 201 USPATFULL on STN
AN 2003:244864 USPATFULL
TI Compounds that bind HER2
IN Dennis, Mark S., San Carlos, CA, UNITED STATES
PA GENENTECH, INC. (U.S. corporation)
PI US 2003171278 A1 20030911
AI US 2002-196394 A1 20020715 (10)
RLI Continuation of Ser. No. US 2000-609721, filed on 30 Jun 2000, ABANDONED
PRAI US 1999-142232P 19990702 (60)
DT Utility
FS APPLICATION
LN.CNT 3598
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000;
530/326.000; 530/327.000; 530/328.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000;
530/326.000; 530/327.000; 530/328.000
IC [7]
ICM: A61K038-10
ICS: A61K038-08; C07K007-08; C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 33 OF 201 USPATFULL on STN
AN 2003:243824 USPATFULL
TI Treating Autoimmune Diseases with Humanized Anti-CD40L Antibody
IN Black, Amelia, Los Getos, CA, UNITED STATES
Hanna, Nabil, Rancho Santa Fee, CA, UNITED STATES
Padlan, Eduardo A., Kensington, MD, UNITED STATES
Newman, Roland A., San Diego, CA, UNITED STATES
PA IDEC PHARMACEUTICALS CORPORATION (U.S. corporation)
PI US 2003170233 A1 20030911
AI US 2002-171681 A1 20020617 (10)
RLI Continuation of ser. No. US 1999-332595, filed on 14 Jun 1999, GRANTED,
Pat. No. US 6506383 Division of Ser. No. US 1995-554840, filed on 7 Nov
1995, GRANTED, Pat. No. US 6001358
DT Utility
FS APPLICATION

LN.CNT 2281
INCL INCLM: 424/141.100
INCLS: 530/388.150
NCL NCLM: 424/141.100
NCLS: 530/388.150
IC [7]
ICM: A61K039-395
ICS: C07K016-42

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 34 OF 201 USPATFULL on STN
AN 2003:239374 USPATFULL
TI Method of producing heteromultimeric mammalian proteins in plants
IN Hein, Mich B., Fallbrook, CA, UNITED STATES
Hiatt, Andrew, San Diego, CA, UNITED STATES
PA The Scripps Research Institute (U.S. corporation)
PI US 2003167534 A1 20030904
AI US 2003-372614 A1 20030225 (10)
RLI Continuation of Ser. No. US 1998-200657, filed on 25 Nov 1998, PENDING
Continuation of Ser. No. US 1996-642406, filed on 3 May 1996, GRANTED,
Pat. No. US 5959177 Continuation-in-part of Ser. No. US 1992-971951,
filed on 5 Nov 1992, GRANTED, Pat. No. US 5639947 Continuation of Ser.
No. US 1990-591823, filed on 2 Oct 1990, GRANTED, Pat. No. US 5202422
Continuation-in-part of Ser. No. US 1989-427765, filed on 27 Oct 1989,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4695
INCL INCLM: 800/288.000
NCL NCLM: 800/288.000
IC [7]
ICM: A01H001-00
ICS: C12N015-82

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 35 OF 201 USPATFULL on STN
AN 2003:201379 USPATFULL
TI Expression and export of angiogenesis inhibitors as immunofusins
IN Lo, Kin-Ming, Lexington, MA, UNITED STATES
Li, Yue, Bedford, MA, UNITED STATES
Gillies, Stephen D., Carlisle, MA, UNITED STATES
PI US 2003139365 A1 20030724
AI US 2002-292418 A1 20021112 (10)
RLI Continuation of Ser. No. US 1999-383315, filed on 25 Aug 1999, ABANDONED
PRAI US 1998-97883P 19980825 (60)
DT Utility
FS APPLICATION
LN.CNT 2327
INCL INCLM: 514/044.000
INCLS: 514/012.000; 435/069.700; 435/320.100; 435/325.000; 530/350.000;
536/023.200
NCL NCLM: 514/044.000
NCLS: 514/012.000; 435/069.700; 435/320.100; 435/325.000; 530/350.000;
536/023.200
IC [7]
ICM: A61K048-00
ICS: C07K014-47; C12P021-02; C12N005-06; A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 36 OF 201 USPATFULL on STN
AN 2003:194129 USPATFULL
TI Binding domain-immunoglobulin fusion proteins
IN Ledbetter, Jeffrey A., Shoreline, WA, UNITED STATES
Hayden-Ledbetter, Martha S., Shoreline, WA, UNITED STATES
PA Genecraft, Inc., Shoreline, WA, UNITED STATES, 98177 (U.S. corporation)
PI US 2003133939 A1 20030717
AI US 2002-53530 A1 20020117 (10)
DT Utility
FS APPLICATION
LN.CNT 4040
INCL INCLM: 424/178.100
INCLS: 435/069.100; 435/320.100; 530/391.100; 435/344.000; 536/023.530
NCL NCLM: 424/178.100
NCLS: 435/069.100; 435/320.100; 530/391.100; 435/344.000; 536/023.530
IC [7]
ICM: A61K039-395

ICS: C07H021-04; C07K016-46; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 37 OF 201 USPATFULL on STN
AN 2003:172748 USPATFULL
TI Binding domain-immunoglobulin fusion proteins
IN Ledbetter, Jeffrey A., Shoreline, WA, UNITED STATES
Hayden-Ledbetter, Martha S., Shoreline, WA, UNITED STATES
Thompson, Peter A., Danville, CA, UNITED STATES
PA Genecraft, Inc., Shoreline, WA (U.S. corporation)
PI US 2003118592 A1 20030626
AI US 2002-207655 A1 20020725 (10)
RLI Continuation-in-part of Ser. No. US 2002-53530, filed on 17 Jan 2002,
PENDING
PRAI US 2001-367358P 20010117 (60)
US 2002-385691P 20020603 (60)
DT Utility
FS APPLICATION
LN.CNT 7939
INCL INCLM: 424/178.100
INCLS: 530/391.100
NCL NCLM: 424/178.100
NCLS: 530/391.100
IC [7]
ICM: A61K039-395
ICS: C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 38 OF 201 USPATFULL on STN
AN 2003:165447 USPATFULL
TI Muscle cells and their use in cardiac repair
IN Edge, Albert, Cambridge, MA, UNITED STATES
Dinsmore, Jonathan, Brookline, MA, UNITED STATES
PI US 2003113301 A1 20030619
AI US 2002-105035 A1 20020321 (10)
RLI Continuation-in-part of Ser. No. US 2000-624885, filed on 24 Jul 2000,
PENDING
PRAI US 1999-145849P 19990723 (60)
DT Utility
FS APPLICATION
LN.CNT 3064
INCL INCLM: 424/093.210
INCLS: 424/093.700
NCL NCLM: 424/093.210
NCLS: 424/093.700
IC [7]
ICM: A61K048-00

L4 ANSWER 39 OF 201 USPATFULL on STN
AN 2003:145864 USPATFULL
TI Human cytokine receptor
IN Presnell, Scott R., Tacoma, WA, UNITED STATES
Xu, Wenfeng, Mukilteo, WA, UNITED STATES
Kindsvogel, Wayne, Seattle, WA, UNITED STATES
Chen, Zhi, Bellevue, WA, UNITED STATES
Hughes, Steven D., Seattle, WA, UNITED STATES
PI US 2003099608 A1 20030529
AI US 2002-104919 A1 20020322 (10)
PRAI US 2001-279222P 20010327 (60)
DT Utility
FS APPLICATION
LN.CNT 9645
INCL INCLM: 424/085.100
INCLS: 435/069.500; 435/320.100; 435/325.000; 530/351.000; 536/023.500
NCL NCLM: 424/085.100
NCLS: 435/069.500; 435/320.100; 435/325.000; 530/351.000; 536/023.500
IC [7]
ICM: A61K038-19
ICS: C07K014-52; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 201 USPATFULL on STN
AN 2003:135731 USPATFULL
TI Transgenic animals for producing specific isotypes of human antibodies
via non-cognate switch regions
IN Green, Larry L., San Francisco, CA, UNITED STATES

Ivanov, Vladimir E., Fremont, CA, UNITED STATES
Davis, C. Geoffrey, Burlingame, CA, UNITED STATES
PI US 2003093820 A1 20030515
AI US 2001-999321 A1 20011130 (9)
PRAI WO 2000-US15782 20000608
DT Utility
FS APPLICATION
LN.CNT 3765
INCL INCLM: 800/008.000
INCLS: 435/069.100; 435/326.000; 435/320.100; 536/023.530
NCL NCLM: 800/008.000
NCLS: 435/069.100; 435/326.000; 435/320.100; 536/023.530
IC [7]
ICM: A01K067-00
ICS: C07H021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 41 OF 201 USPATFULL on STN
AN 2003:119705 USPATFULL
TI Fusion molecules and treatment of IgE-mediated allergic diseases
IN Saxon, Andrew, Santa Monica, CA, UNITED STATES
Zhang, Ke, Los Angeles, CA, UNITED STATES
Zhu, Daocheng, Los Angeles, CA, UNITED STATES
PI US 2003082190 A1 20030501
AI US 2001-847208 A1 20010501 (9)
DT Utility
FS APPLICATION
LN.CNT 7500
INCL INCLM: 424/178.100
INCLS: 530/391.100; 435/069.700; 435/320.100; 435/334.000; 536/023.530
NCL NCLM: 424/178.100
NCLS: 530/391.100; 435/069.700; 435/320.100; 435/334.000; 536/023.530
IC [7]
ICM: A61K039-395
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 42 OF 201 USPATFULL on STN
AN 2003:112973 USPATFULL
TI Mouse cytokine receptor
IN Presnell, Scott R., Tacoma, WA, UNITED STATES
Xu, Wenfeng, Mukilteo, WA, UNITED STATES
Kindsvogel, Wayne, Seattle, WA, UNITED STATES
Chen, Zhi, Bellevue, WA, UNITED STATES
PI US 2003077706 A1 20030424
AI US 2002-90365 A1 20020304 (10)
PRAI US 2001-273035P 20010302 (60)
US 2001-279232P 20010327 (60)
DT Utility
FS APPLICATION
LN.CNT 7834
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000
IC [7]
ICM: A61K038-17
ICS: C07K014-715; C12Q001-68; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 43 OF 201 USPATFULL on STN
AN 2003:112545 USPATFULL
TI Recombinant anti-CD4 antibodies for human therapy
IN Hanna, Nabil, Olivenhain, CA, UNITED STATES
Newman, Roland Anthony, San Diego, CA, UNITED STATES
Reff, Mitchell Elliot, San Diego, CA, UNITED STATES
PA IDEC Pharmaceuticals Corporation (U.S. corporation)
PI US 2003077275 A1 20030424
AI US 2002-211357 A1 20020805 (10)
RLI Division of Ser. No. US 2000-612914, filed on 10 Jul 2000, PENDING
Continuation of Ser. No. US 1995-523894, filed on 6 Sep 1995, GRANTED,
Pat. No. US 6136310 continuation of Ser. No. US 1995-476237, filed on 7
Jun 1995, GRANTED, Pat. No. US 5756096 Continuation-in-part of Ser. No.
US 1995-379072, filed on 25 Jan 1995, GRANTED, Pat. No. US 5658570
Continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, ABANDONED
Continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992,

ABANDONED Continuation of Ser. No. US 1991-735064, filed on 25 Jul 1991,
ABANDONED

DT Utility
FS APPLICATION
LN.CNT 3560
INCL INCLM: 424/133.100
INCLS: 530/387.300; 536/023.530; 435/327.000; 435/363.000; 435/320.100;
435/069.100
NCL NCLM: 424/133.100
NCLS: 530/387.300; 536/023.530; 435/327.000; 435/363.000; 435/320.100;
435/069.100

IC [7]
ICM: A61K039-395
ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 44 OF 201 USPATFULL on STN
AN 2003:92706 USPATFULL
TI Fusion molecules and methods for treatment of immune diseases
IN Saxon, Andrew, Santa Monica, CA, UNITED STATES
PI US 2003064063 A1 20030403
AI US 2001-439 A1 20011024 (10)
RLI Continuation-in-part of Ser. No. US 2001-847208, filed on 1 May 2001,
PENDING

DT Utility
FS APPLICATION
LN.CNT 4242
INCL INCLM: 424/131.100
INCLS: 530/387.200; 435/069.700; 435/327.000; 435/320.100; 536/023.530
NCL NCLM: 424/131.100
NCLS: 530/387.200; 435/069.700; 435/327.000; 435/320.100; 536/023.530
IC [7]
ICM: A61K039-395
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-42

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 45 OF 201 USPATFULL on STN
AN 2003:86229 USPATFULL
TI Methods to generate and identify monoclonal antibodies to a large number
of human antigens
IN Chang, Nancy T., Houston, TX, UNITED STATES
PI US 2003059834 A1 20030327
AI US 2002-61910 A1 20020201 (10)
PRAI US 2001-265701P 20010201 (60)

DT Utility
FS APPLICATION
LN.CNT 502
INCL INCLM: 435/007.100
INCLS: 435/069.100; 435/070.210; 435/320.100; 530/388.100
NCL NCLM: 435/007.100
NCLS: 435/069.100; 435/070.210; 435/320.100; 530/388.100
IC [7]
ICM: G01N033-53
ICS: C12P021-04; C07K016-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 46 OF 201 USPATFULL on STN
AN 2003:70942 USPATFULL
TI Enhancement of antibody-cytokine fusion protein mediated immune
responses by combined treatment with immunocytokine uptake enhancing
agents
IN Gillies, Stephen D., Carlisle, MA, UNITED STATES
Lan, Yan, Belmont, MA, UNITED STATES
Holden, Sylvia, Woburn, MA, UNITED STATES
PI US 2003049227 A1 20030313
AI US 2001-896909 A1 20010629 (9)
PRAI US 2000-215038P 20000629 (60)

DT Utility
FS APPLICATION
LN.CNT 1559
INCL INCLM: 424/085.100
INCLS: 424/178.100; 530/351.000
NCL NCLM: 424/085.100
NCLS: 424/178.100; 530/351.000
IC [7]
ICM: A61K039-395

ICS: A61K038-19; C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 47 OF 201 USPATFULL on STN
AN 2003:57473 USPATFULL
TI In vitro modification of glycosylation patterns of recombinant glycopeptides
IN Bayer, Robert J., San Diego, CA, UNITED STATES
PA Neose Technologies, Inc., Horsham, PA, UNITED STATES (U.S. corporation)
PI US 2003040037 A1 20030227
AI US 2002-219197 A1 20020813 (10)
RLI Continuation of Ser. No. US 2001-855320, filed on 14 May 2001, PENDING
PRAI WO 2001-US15693 20010514
US 2000-203851P 20000512 (60)
DT Utility
FS APPLICATION
LN.CNT 2071
INCL INCLM: 435/068.100
INCLS: 435/069.100; 435/193.000; 435/252.300
NCL NCLM: 435/068.100
NCLS: 435/069.100; 435/193.000; 435/252.300
IC [7]
ICM: C12P021-06
ICS: C12N009-10; C12N001-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 48 OF 201 USPATFULL on STN
AN 2003:52386 USPATFULL
TI Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
IN Robl, James M., Belchertown, MA, UNITED STATES
Goldsby, Richard A., Leverett, MA, UNITED STATES
Ferguson, Stacy E., Worcester, MA, UNITED STATES
Kuroiwa, Yoshimi, Takasaki, JAPAN
Tomizuka, Kazuma, Takasaki, JAPAN
Ishida, Isao, Isehara, JAPAN
PI US 2003037347 A1 20030220
AI US 2001-988115 A1 20011116 (9)
RLI Continuation-in-part of Ser. No. US 2000-714185, filed on 17 Nov 2000, PENDING
PRAI US 2001-311625P 20010809 (60)
US 2000-256458P 20001220 (60)
US 1999-166410P 19991119 (60)
DT Utility
FS APPLICATION
LN.CNT 3863
INCL INCLM: 800/006.000
INCLS: 800/015.000; 800/014.000; 800/016.000; 800/017.000; 435/326.000
NCL NCLM: 800/006.000
NCLS: 800/015.000; 800/014.000; 800/016.000; 800/017.000; 435/326.000
IC [7]
ICM: A01K067-027
ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 49 OF 201 USPATFULL on STN
AN 2003:39264 USPATFULL
TI METHOD OF USE OF TRANSGENIC PLANT EXPRESSED ANTIBODIES
IN Hein, Mich B., Fallbrook, CA, UNITED STATES
Hiatt, Andrew, San Diego, CA, UNITED STATES
Ma, Julian K-C, London, UNITED KINGDOM
PI US 2003028913 A1 20030206
AI US 2000-491322 A1 20000125 (9)
RLI Division of Ser. No. US 1998-200657, filed on 25 Nov 1998, PENDING
Continuation of Ser. No. US 1996-642406, filed on 3 May 1996, GRANTED,
Pat. No. US 5959177 Continuation of Ser. No. US 1992-971951, filed on 5
Nov 1992, GRANTED, Pat. No. US 5639947 Continuation of Ser. No. US
1990-591823, filed on 2 Oct 1990, GRANTED, Pat. No. US 5202422
Continuation-in-part of Ser. No. US 1989-427765, filed on 27 Oct 1989,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4767
INCL INCLM: 800/278.000
NCL NCLM: 800/278.000
IC [7]

ICM: C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 50 OF 201 USPATFULL on STN
AN 2003:37608 USPATFULL
TI Cytokine receptor zcytor19
IN Presnell, Scott R., Tacoma, WA, UNITED STATES
Xu, Wenfeng, Mukilteo, WA, UNITED STATES
Novak, Julia E., Bainbridge Island, WA, UNITED STATES
Whitmore, Theodore E., Redmond, WA, UNITED STATES
Grant, Francis J., Seattle, WA, UNITED STATES
PI US 2003027253 A1 20030206
AI US 2001-995898 A1 20011128 (9)
PRAI US 2000-253561P 20001128 (60)
US 2001-267211P 20010207 (60)
DT Utility
FS APPLICATION
LN.CNT 7156
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500; 435/006.000
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-715; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 51 OF 201 USPATFULL on STN
AN 2003:17032 USPATFULL
TI Non-agonistic antibodies to human gp39, compositions containing, and
therapeutic use thereof
IN Darrell, Anderson, Escondido, CA, UNITED STATES
Pan, Li-Zhen, San Diego, CA, UNITED STATES
Hanna, Nabil, Rancho Santa Fe, CA, UNITED STATES
Rastetter, William H., Rancho Santa Fe, CA, UNITED STATES
Kloetzer, William S., Carlsbad, CA, UNITED STATES
PI US 2003012781 A1 20030116
AI US 2001-874141 A1 20010606 (9)
PRAI US 2000-209584P 20000606 (60)
DT Utility
FS APPLICATION
LN.CNT 2456
INCL INCLM: 424/131.100
INCLS: 424/093.210
NCL NCLM: 424/131.100
NCLS: 424/093.210
IC [7]
ICM: A61K048-00
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 52 OF 201 USPATFULL on STN
AN 2003:3494 USPATFULL
TI Vitro modification of glycosylation patterns of recombinant
glycopeptides
IN Bayer, Robert J., San Diego, CA, UNITED STATES
PA Neose Technologies, Inc., Horsham, PA, UNITED STATES (U.S. corporation)
PI US 2003003529 A1 20030102
AI US 2002-198806 A1 20020719 (10)
RLI Division of Ser. No. US 2001-855320, filed on 14 May 2001, PENDING
PRAI WO 2001-US15693 20010514
US 2000-203851P 20000512 (60)
DT Utility
FS APPLICATION
LN.CNT 2076
INCL INCLM: 435/068.100
INCLS: 435/069.100; 435/193.000; 530/322.000
NCL NCLM: 435/068.100
NCLS: 435/069.100; 435/193.000; 530/322.000
IC [7]
ICM: C12P021-06
ICS: C12N009-10; C07K009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 53 OF 201 USPATFULL on STN
AN 2003:240319 USPATFULL

TI Multiple cytokine protein complexes
 IN Gillies, Stephen D., Carlisle, MA, United States
 Lo, Kin-Ming, Lexington, MA, United States
 PA EMD Lexigen Research Center Corp., Billerica, MA, United States (U.S. corporation)
 PI US 6617135 B1 20030909
 AI US 2000-634368 20000809 (9)
 PRAI US 1999-147924P 19990809 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3036
 INCL INCLM: 435/069.700
 INCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 435/069.520; 530/350.000; 530/387.300; 530/402.000
 NCL NCLM: 435/069.700
 NCLS: 435/069.520; 435/252.300; 435/254.110; 435/320.100; 435/325.000; 530/350.000; 530/387.300; 530/402.000
 IC [7]
 ICM: C12N015-62
 ICS: C12N015-63; C07K014-54
 EXF 424/134.1; 424/185.1; 424/192.1; 435/69.7; 435/69.1; 435/252.3; 435/254.11; 435/320.1; 435/325; 435/69.52; 530/387.3; 530/350; 530/387.1; 530/402; 536/23.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 54 OF 201 USPATFULL on STN
 AN 2003:13072 USPATFULL
 TI Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies
 IN Black, Amelia, Cardiff, CA, United States
 Hanna, Nabil, Olivenhian, CA, United States
 Padlan, Eduardo A., Kensington, MD, United States
 Newman, Roland A., San Diego, CA, United States
 PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
 PI US 6506383 B1 20030114
 AI US 1999-332595 19990614 (9)
 RLI Division of Ser. No. US 1995-554840, filed on 7 Nov 1995, now patented, Pat. No. US 6001358
 DT Utility
 FS GRANTED
 LN.CNT 2606
 INCL INCLM: 424/154.100
 INCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100; 424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750
 NCL NCLM: 424/154.100
 NCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100; 424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750
 IC [7]
 ICM: A61K039-395
 ICS: C07K016-28
 EXF 424/130.1; 424/133.1; 424/144.1; 424/173.1; 530/387.1; 530/388.2; 530/388.73
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 55 OF 201 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
 DUPLICATE 3
 AN 2003-02087 BIOTECHDS
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder, e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked to a peptide capable of binding amyloidogenic protein;
 vector-mediated gene transfer, expression in host cell for recombinant protein production and disease therapy
 AU GEFTER M L; ISRAEL D I; JOYAL J L; GOSSELIN M
 PA PRAECIS PHARM INC
 PI WO 2002042462 30 May 2002
 AI WO 2001-US44581 27 Nov 2001
 PRAI US 2000-257186 20 Dec 2000; US 2000-253302 27 Nov 2000
 DT Patent
 LA English
 OS WPI: 2002-636427 [68]

L4 ANSWER 56 OF 201 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 4

AN 10189297 IFIPAT;IFIUDB;IFICDB
 TI THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR TREATING AN
 AMYLOIDOGENIC DISEASE; COMPOUND FOR USE IN THE TREATMENT OF ALZHEIMER'S
 AND CREUZFELDT-JACOB DISEASES
 IN Gefter Malcolm L; Gosselin Michael; Israel David I; Joyal John L
 PA Praecis Pharmaceuticals Inc (46269)
 PI US 2002133001 A1 20020919
 AI US 2001-996357 20011127
 PRAI US 2000-250198P 20001129 (Provisional)
 US 2000-253302P 20001127 (Provisional)
 US 2000-257186P 20001220 (Provisional)
 FI US 2002133001 20020919
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 CLMN 78
 GI 13 Figure(s).
 FIG. 1 depicts a Western blot analysis of COS cell lysates and medium
 harvested from COS cells expressing the FC region of mouse IgG1 fused to
 amino acid residues 1-40, 1-42, 10-25, 1630, 17-21, or 17-21 (A21L) of
 P-amyloid with or without an Nterminal triple glycine cap.
 FIG. 2 depicts an immunohistochemistry analysis of coronal brain sections
 from 20-22 week mice transgenic for both the Swedish mutation of amyloid
 precursor protein and presenilin of mouse IgG1 fused to various segments
 of P-amyloid, medium from nontransfected COS cells, or anti-beta-amyloid
 polyclonal antibody.
 FIG. 3 depicts the synthetic oligonucleotides that were used to assemble
 the synthetic APP/IgG gene. These oligonucleotides contain unique
 restriction endonuclease sites needed for the assembly.
 FIG. 4 is a schematic representation of the pTig expression vector.
 FIG. 5 is a schematic representation of the assembly of synthetic A beta
 1-40 and A beta 1-42, with and without a triple Gly linker group between
 the tPA propeptide and the beta -amyloid peptide.
 FIG. 6 depicts the DNA sequence, amino acid composition, and restriction
 endonuclease recognition sites of the synthetic beta-amyloid gene.
 FIG. 7A depicts the sequence of the oligonucleotides used to assemble
 subfragments of the synthetic beta-amyloid gene and a compilation of the
 chimeric beta-amyloid/IgG1 constructs that were made.
 FIG. 7B depicts the sequence of the oligonucleotides used to assemble
 subfragments of the synthetic beta-amyloid gene and a compilation of the
 chimeric beta-amyloid/IgG1 constructs that were made.
 FIG. 8 is a graph demonstrating that ****Fc**** ****receptor****
 -mediated fibril uptake by cells occurs in the presence of either the A
 beta (1630)-Fc fusion protein or the alpha-beta-amyloid antibody.
 FIG. 9 is a graph demonstrating that the A beta (16-30)-Fc fusion protein
 interferes with the binding of soluble betaamyloid peptide to amyloid
 fibrils.
 FIG. 10 is brain section stained with Thioflavin S, demonstrating that
 treatment of an Alzheimer's disease model transgenic mouse with the A
 beta (16-30)-Fc fusion protein results in a decrease in plaque at the
 site of administration.
 FIG. 11 depicts the coding region of the tPA Delta pro/16-30/Fc cDNA
 synthetic gene synthetic gene (SEQ ID NO:11).
 FIG. 12 depicts the amino acid sequence of the tPA Delta pro/1630/Fc
 fusion protein (SEQ ID NO:12). Annotated functional elements are also
 shown. The A beta (16-30)-Fc protein is set forth herein as SEQ ID NO: 13

L4 ANSWER 57 OF 201 USPATFULL on STN DUPLICATE 5
 AN 2002:251724 USPATFULL
 TI Soluble zalpha11 cytokine receptors
 IN Sprecher, Cindy A., Seattle, WA, UNITED STATES
 Novak, Julia E., Bainbridge Island, WA, UNITED STATES
 West, James W., Seattle, WA, UNITED STATES
 Presnell, Scott R., Tacoma, WA, UNITED STATES
 Holly, Richard D., Seattle, WA, UNITED STATES
 Nelson, Andrew J., Shoreline, WA, UNITED STATES
 PI US 2002137677 A1 20020926
 US 6777539 B2 20040817
 AI US 2001-825561 A1 20010403 (9)
 PRAI US 2000-194731P 20000405 (60)
 US 2000-222121P 20000728 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8392
 INCL INCLM: 514/012.000
 INCLS: 530/350.000; 536/023.500; 435/069.100; 435/325.000; 435/320.100

NCL NCLM: 530/350.000
NCLS: 530/351.000
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C07K014-705; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 58 OF 201 USPATFULL on STN DUPLICATE 6
AN 2002:236242 USPATFULL
TI Novel cytokine zalphall Ligand
IN Novak, Julia E., Bainbridge Island, WA, UNITED STATES
Presnell, Scott R., Tacoma, WA, UNITED STATES
Sprecher, Cindy A., Seattle, WA, UNITED STATES
Foster, Donald C., Lake Forest Park, WA, UNITED STATES
Holly, Richard D., Seattle, WA, UNITED STATES
Gross, Jane A., Seattle, WA, UNITED STATES
Johnston, Janet V., Seattle, WA, UNITED STATES
Nelson, Andrew J., Shoreline, WA, UNITED STATES
Dillon, Stacey R., Seattle, WA, UNITED STATES
Hammond, Angela K., Maple Valley, WA, UNITED STATES
PI US 2002128446 A1 20020912
US 6605272 B2 20030812
AI US 2001-923246 A1 20010803 (9)
RLI Division of Ser. No. US 2000-522217, filed on 9 Mar 2000, PATENTED
PRAI US 1999-123547P 19990309 (60)
US 1999-123904P 19990311 (60)
US 1999-142013P 19990701 (60)
DT Utility
FS APPLICATION
LN.CNT 8753
INCL INCLM: 530/351.000
INCLS: 435/069.500; 536/023.500; 435/320.100; 435/325.000
NCL NCLM: 424/085.200
NCLS: 424/085.100; 424/169.100; 424/173.100; 424/174.100; 514/002.000;
514/012.000

IC [7]
ICM: C07K014-52
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 59 OF 201 USPATFULL on STN
AN 2002:272465 USPATFULL
TI Recombinant antibodies for human therapy
IN Newman, Roland A., San Diego, CA, UNITED STATES
Hanna, Nabil, Olivenhain, CA, UNITED STATES
Raab, Ronald W., San Diego, CA, UNITED STATES
PA IDEC Pharmaceuticals Corporation, San Diego, CA (U.S. corporation)
PI US 2002150580 A1 20021017
AI US 2001-850165 A1 20010508 (9)
RLI Continuation of Ser. No. US 1998-82472, filed on 21 May 1998, ABANDONED
Continuation of Ser. No. US 1995-476237, filed on 7 Jun 1995, GRANTED,
Pat. No. US 5756096 Continuation-in-part of Ser. No. US 1995-397072,
filed on 17 Apr 1995, ABANDONED Continuation of Ser. No. US 1992-912292,
filed on 10 Jul 1992, ABANDONED Continuation-in-part of Ser. No. US
1992-856281, filed on 23 Mar 1992, ABANDONED Continuation-in-part of
Ser. No. US 1991-735064, filed on 25 Jul 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3119
INCL INCLM: 424/154.100
INCLS: 530/388.800; 435/069.100; 435/326.000; 435/320.100; 536/023.530
NCL NCLM: 424/154.100
NCLS: 530/388.800; 435/069.100; 435/326.000; 435/320.100; 536/023.530
IC [7]
ICM: A61K039-395
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 60 OF 201 USPATFULL on STN
AN 2002:266431 USPATFULL
TI MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF
IN BRISKIN, MICHAEL J., LEXINGTON, MA, UNITED STATES
RINGLER, DOUGLAS J., REVERE, MA, UNITED STATES
PICARELLA, DOMINIC, SUDBURY, MA, UNITED STATES
NEWMAN, WALTER, BOSTON, MA, UNITED STATES
PI US 2002147314 A1 20021010

AI US 1997-875849 A1 19970908 (8)
WO 1996-US2153 19960212
DT Utility
FS APPLICATION
LN.CNT 3801
INCL INCLM: 530/391.100
INCLS: 530/391.700; 530/395.000; 530/402.000; 530/866.000
NCL NCLM: 530/391.100
NCLS: 530/391.700; 530/395.000; 530/402.000; 530/866.000
IC [7]
ICM: A61K039-395
ICS: C07K017-14; C12P021-08; C07K016-00; C07K001-00; C08H001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 61 OF 201 USPATFULL on STN
AN 2002:266429 USPATFULL
TI Hybrid antibodies and uses thereof
IN O'Keefe, Theresa, Waltham, MA, UNITED STATES
Rao, Patricia, Acton, MA, UNITED STATES
PI US 2002147312 A1 20021010
AI US 2002-60714 A1 20020130 (10)
PRAI US 2001-265914P 20010202 (60)
DT Utility
FS APPLICATION
LN.CNT 2979
INCL INCLM: 530/387.300
INCLS: 530/388.150
NCL NCLM: 530/387.300
NCLS: 530/388.150
IC [7]
ICM: C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 62 OF 201 USPATFULL on STN
AN 2002:258804 USPATFULL
TI GENERATION OF MODIFIED MOLECULES WITH INCREASED SERUM HALF-LIVES
IN GALLO, MICHAEL, SAN JOSE, CA, UNITED STATES
JUNGHANS, RICHARD, BOSTON, MA, UNITED STATES
FOORD, ORIT, FOSTER CITY, CA, UNITED STATES
PI US 2002142374 A1 20021003
AI US 1999-375924 A1 19990817 (9)
PRAI US 1998-96868P 19980817 (60)
DT Utility
FS APPLICATION
LN.CNT 2060
INCL INCLM: 435/069.100
INCLS: 435/069.600; 530/387.300; 530/388.100; 530/388.230
NCL NCLM: 435/069.100
NCLS: 435/069.600; 530/387.300; 530/388.100; 530/388.230
IC [7]
ICM: C12P021-06
ICS: C12P021-04; C12P021-08; C07K016-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 63 OF 201 USPATFULL on STN
AN 2002:227904 USPATFULL
TI In vitro methods of producing and identifying immunoglobulin molecules
in eukaryotic cells
IN Zauderer, Maurice, Pittsford, NY, UNITED STATES
Smith, Ernest S., Ontario, NY, UNITED STATES
PA University of Rochester, Rochester, NY, 14642 (U.S. corporation)
PI US 2002123057 A1 20020905
AI US 2001-987456 A1 20011114 (9)
PRAI US 2000-249268P 20001117 (60)
US 2001-262067P 20010118 (60)
US 2001-271424P 20010227 (60)
US 2001-298087P 20010615 (60)
DT Utility
FS APPLICATION
LN.CNT 7215
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/069.100; 435/326.000; 435/320.100; 536/023.530
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/326.000; 435/320.100; 536/023.530
IC [7]
ICM: C12Q001-68

ICS: G01N033-53; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 64 OF 201 USPATFULL on STN
AN 2002:221013 USPATFULL
TI ErbB4 antagonists
IN Gerritsen, Mary E., San Mateo, CA, UNITED STATES
Sliwkowski, Mark X., San Carlos, CA, UNITED STATES
PI US 2002119148 A1 20020829
AI US 2001-940101 A1 20010827 (9)
PRAI US 2000-229679P 20000901 (60)
US 2001-265516P 20010131 (60)
DT Utility
FS APPLICATION
LN.CNT 3728
INCL INCLM: 424/143.100
NCL NCLM: 424/143.100
IC [7]
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 65 OF 201 USPATFULL on STN
AN 2002:157065 USPATFULL
TI Expression and export of interferon-alpha proteins as Fc fusion proteins
IN Lo, Kin-Ming, Lexington, MA, UNITED STATES
Sun, Yaping, Arlington, MA, UNITED STATES
Gillies, Stephen D., Carlisle, MA, UNITED STATES
PI US 2002081664 A1 20020627
AI US 2001-977034 A1 20011011 (9)
RLI Division of Ser. No. US 2000-575503, filed on 19 May 2000, ABANDONED
PRAI US 1999-134895P 19990519 (60)
DT Utility
FS APPLICATION
LN.CNT 1923
INCL INCLM: 435/069.500
INCLS: 435/325.000; 435/320.100; 536/023.530; 530/351.000; 530/391.100
NCL NCLM: 435/069.500
NCLS: 435/325.000; 435/320.100; 536/023.530; 530/351.000; 530/391.100
IC [7]
ICM: C12P021-02
ICS: C07H021-04; C12N005-06; C07K016-46

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 66 OF 201 USPATFULL on STN
AN 2002:148269 USPATFULL
TI Multivalent target binding protein
IN Leung, Shui-on, Shatin, HONG KONG
PI US 2002076406 A1 20020620
AI US 2001-911610 A1 20010725 (9)
PRAI US 2000-220782P 20000725 (60)
DT Utility
FS APPLICATION
LN.CNT 1776
INCL INCLM: 424/135.100
NCL NCLM: 424/135.100
IC [7]
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 67 OF 201 USPATFULL on STN
AN 2002:98889 USPATFULL
TI Methods for modulating T cell unresponsiveness
IN Boussiotis, Vassiliki A., Brookline, MA, UNITED STATES
Freeman, Gordon J., Brookline, MA, UNITED STATES
Nadler, Lee M., Newton, MA, UNITED STATES
PA Dana Farber Cancer institute (U.S. corporation)
PI US 2002051784 A1 20020502
AI US 2001-995519 A1 20011128 (9)
RLI Continuation of Ser. No. US 1995-457483, filed on 1 Jun 1995, PENDING
Continuation-in-part of Ser. No. US 1994-207932, filed on 8 Mar 1994,
PENDING Continuation-in-part of Ser. No. WO 1995-US2916, filed on 8 Mar
1995, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 1803
INCL INCLM: 424/144.100

INCLS: 424/146.100
NCL NCLM: 424/144.100
NCLS: 424/146.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 68 OF 201 USPATFULL on STN
AN 2002:48297 USPATFULL
TI Transgenic avian species for making human and chimeric antibodies
IN Singh, Sujay, San Diego, CA, UNITED STATES
Dias, Peter, Carlsbad, CA, UNITED STATES
PI US 2002028488 A1 20020307
AI US 2001-884579 A1 20010618 (9)
PRAI US 2000-212456P 20000619 (60)
DT Utility
FS APPLICATION
LN.CNT 2642
INCL INCLM: 435/070.210
INCLS: 800/019.000; 530/388.100
NCL NCLM: 435/070.210
NCLS: 800/019.000; 530/388.100
IC [7]
ICM: A01K067-027
ICS: C12P021-04; C07K016-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 69 OF 201 USPATFULL on STN
AN 2002:32520 USPATFULL
TI In vitro modification of glycosylation patterns of recombinant
glycopeptides
IN Bayer, Robert, San Diego, CA, UNITED STATES
PI US 2002019342 A1 20020214
AI US 2001-855320 A1 20010514 (9)
PRAI US 2000-203851P 20000512 (60)
DT Utility
FS APPLICATION
LN.CNT 2069
INCL INCLM: 514/008.000
INCLS: 435/014.000
NCL NCLM: 514/008.000
NCLS: 435/014.000
IC [7]
ICM: A61K038-16
ICS: C12Q001-54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 70 OF 201 USPATFULL on STN
AN 2002:21834 USPATFULL
TI Human cytokine receptor
IN Presnell, Scott R, Tacoma, WA, UNITED STATES
Xu, Wenfeng, Mukilteo, WA, UNITED STATES
Kindsvogel, Wayne, Seattle, WA, UNITED STATES
Chen, Zhi, Seattle, WA, UNITED STATES
PI US 2002012669 A1 20020131
AI US 2000-728911 A1 20001201 (9)
PRAI US 1999-169049P 19991203 (60)
US 2000-232219P 20000913 (60)
US 2000-244610P 20001031 (60)
DT Utility
FS APPLICATION
LN.CNT 7478
INCL INCLM: 424/192.100
INCLS: 530/350.000; 536/023.500; 435/348.000; 435/326.000; 435/410.000;
435/252.100; 435/254.100; 435/255.100; 435/317.100; 435/069.100;
530/387.200; 530/388.100; 530/387.300; 530/389.100; 530/391.100;
514/012.000; 435/007.100; 435/006.000
NCL NCLM: 424/192.100
NCLS: 530/350.000; 536/023.500; 435/348.000; 435/326.000; 435/410.000;
435/252.100; 435/254.100; 435/255.100; 435/317.100; 435/069.100;
530/387.200; 530/388.100; 530/387.300; 530/389.100; 530/391.100;
514/012.000; 435/007.100; 435/006.000
IC [7]
ICM: A61K038-00
ICS: C12Q001-68; C07H021-04; A61K039-00; C12N001-20; C12N001-16;
C12N001-14; C12N001-12; C12P021-06; G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 71 OF 201 USPATFULL on STN
AN 2002:326103 USPATFULL
TI Multimeric immunotoxins
IN Valleria, Daniel A., St. Louis Park, MN, United States
Blazar, Bruce R., Golden Valley, MN, United States
PA Regents of the University of Minnesota, Minneapolis, MN, United States
(U.S. corporation)
PI US 6492498 B1 20021210
AI US 1999-440344 19991115 (9)
DT Utility
FS GRANTED
LN.CNT 1661
INCL INCLM: 530/391.700
INCLS: 530/300.000; 530/350.000; 530/387.100; 424/183.100
NCL NCLM: 530/391.700
NCLS: 424/183.100; 530/300.000; 530/350.000; 530/387.100
IC [7]
ICM: C07K016-00
EXF 530/387.1; 530/387.3; 530/388.75; 530/388.8; 530/388.85; 530/300;
530/350; 424/130.1; 424/134.1; 424/181.1; 424/183.1; 512/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 72 OF 201 USPATFULL on STN
AN 2002:238640 USPATFULL
TI Methods for stimulating T cell responses to tumor cells expressing LFA-3
and a CD28 or CTLA4 ligand
IN Boussiotis, Vassiliki A., Brookline, MA, United States
Freeman, Gordon J., Brookline, MA, United States
Nadler, Lee M., Newton, MA, United States
PA Dana-Farber Cancer Institute, UNITED STATES (non-U.S. corporation)
PI US 6451305 B1 20020917
AI US 1995-457483 19950601 (8)
RLI Continuation-in-part of Ser. No. US 1994-207932, filed on 8 Mar 1994
Continuation-in-part of Ser. No. WO 1995-US2916, filed on 8 Mar 1995
DT Utility
FS GRANTED
LN.CNT 1671
INCL INCLM: 424/093.210
INCLS: 424/093.200; 424/093.700; 435/325.000; 435/365.100; 435/440.000;
435/455.000
NCL NCLM: 424/093.210
NCLS: 424/093.200; 424/093.700; 435/325.000; 435/365.100; 435/440.000;
435/455.000
IC [7]
ICM: A61K048-00
ICS: C12N005-10
EXF 424/93.2; 424/93.21; 435/325; 435/365.1; 435/440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 73 OF 201 USPATFULL on STN
AN 2002:216830 USPATFULL
TI Methods of treating autoimmune diseases with gp39-specific antibodies
IN Black, Amelia, Cardiff, CA, United States
Hanna, Nabil, Olivenhian, CA, United States
Padlan, Eduardo A., Kensington, MD, United States
Newman, Roland A., San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
PI US 6440418 B1 20020827
AI US 1997-925339 19970908 (8)
RLI Continuation-in-part of Ser. No. US 1995-554840, filed on 7 Nov 1995,
now patented, Pat. No. US 6001358
DT Utility
FS GRANTED
LN.CNT 2625
INCL INCLM: 424/154.100
INCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100;
424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100;
530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750
NCL NCLM: 424/154.100
NCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100;
424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100;
530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750
IC [7]

ICM: A61K039-395
ICS: C07K016-28
EXF 424/130.1; 424/133.1; 424/141.1; 424/153.1; 424/173.1; 530/387.1;
530/388.2; 530/388.73
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 74 OF 201 USPATFULL on STN
AN 2002:168417 USPATFULL
TI Transgenic plants expressing assembled secretory antibodies
IN Hein, Mich B., Fallbrook, CA, United States
Hiatt, Andrew, San Diego, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 6417429 B1 20020709
AI US 1998-199534 19981125 (9)
RLI Continuation of Ser. No. US 1996-642406, filed on 3 May 1996, now patented, Pat. No. US 5959177, issued on 28 Sep 1999
Continuation-in-part of Ser. No. US 1992-971951, filed on 5 Nov 1992, now patented, Pat. No. US 5639947, issued on 17 Jun 1997 Continuation of Ser. No. US 1990-591823, filed on 2 Oct 1990, now patented, Pat. No. US 5202422, issued on 13 Apr 1993 Continuation-in-part of Ser. No. US 1989-427765, filed on 27 Oct 1989, now abandoned
DT Utility
FS GRANTED
LN.CNT 4784
INCL INCLM: 800/288.000
INCLS: 800/295.000; 800/298.000; 800/278.000; 536/023.600; 536/023.700; 536/024.100; 536/023.530; 435/419.000; 435/468.000
NCL NCLM: 800/288.000
NCLS: 435/419.000; 435/468.000; 536/023.530; 536/023.600; 536/023.700; 536/024.100; 800/278.000; 800/295.000; 800/298.000
IC [7]
ICM: C12N016-00
ICS: A01H003-00; A01H005-00
EXF 800/295; 800/298; 800/278; 800/288; 536/23.6; 536/23.7; 536/24.1; 536/23.53; 435/419; 435/468; 530/388.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 75 OF 201 USPATFULL on STN
AN 2002:143943 USPATFULL
TI Hybrid immunoglobulins
IN Capon, Daniel J., San Mateo, CA, United States
Lasky, Laurence A., Sausalito, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6406697 B1 20020618
AI US 1997-906549 19970805 (8)
RLI Continuation of Ser. No. US 1995-451848, filed on 26 May 1995, now patented, Pat. No. US 5714147 Continuation of Ser. No. US 1994-185670, filed on 21 Jan 1994, now patented, Pat. No. US 5514582 Continuation of Ser. No. US 1992-986931, filed on 8 Dec 1992, now patented, Pat. No. US 5428130 Continuation of Ser. No. US 1991-808122, filed on 16 Dec 1991, now patented, Pat. No. US 5225538 Division of Ser. No. US 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964 Continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989, now patented, Pat. No. US 5089833
DT Utility
FS GRANTED
LN.CNT 2685
INCL INCLM: 424/178.100
INCLS: 435/069.700; 514/002.000; 530/350.000; 536/023.400
NCL NCLM: 424/178.100
NCLS: 435/069.700; 514/002.000; 530/350.000; 536/023.400
IC [7]
ICM: C07K016-46
ICS: C12N015-62
EXF 435/69.7; 530/350; 424/178.1; 536/23.4; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 76 OF 201 USPATFULL on STN
AN 2002:122462 USPATFULL
TI Directed switch-mediated DNA recombination
IN Jakobovits, Aya, Menlo Park, CA, United States
Gallo, Michael Lajos, San Jose, CA, United States
Yang, Xiao-Ping, Foster City, CA, United States
PA Abgenix, Inc., Fremont, CA, United States (U.S. corporation)

Japan Tobacco, Inc., Tokyo, JAPAN (non-U.S. corporation)
 PI US 6395515 B1 20020528
 AI US 1999-369635 19990806 (9)
 RLI Continuation of ser. No. US 1997-878166, filed on 17 Jun 1997, now
 patented, Pat. No. US 5985615 Continuation of ser. No. US 1996-619109,
 filed on 20 Mar 1996, now patented, Pat. No. US 5714352
 DT Utility
 FS GRANTED
 LN.CNT 1361
 INCL INCLM: 435/069.600
 INCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100; 800/004.000;
 800/014.000; 800/025.000
 NCL NCLM: 435/069.600
 NCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100; 800/004.000;
 800/014.000; 800/025.000
 IC [7]
 ICM: C12P021-04
 ICS: C12N015-00; C12N015-09; C12N015-63; C12N015-70
 EXF 800/4; 800/14; 800/25; 435/69.6; 435/325; 435/320.1; 435/455; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 77 OF 201 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 DUPLICATE
 AN 2002:34568735 BIOTECHNO
 TI ***Immunoglobulin*** ***heavy*** ***chain*** ***constant***
 regions regulate immunity and tolerance to idiotypes of antibody
 variable regions
 AU Reitan S.K.; Hannestad K.
 CS K. Hannestad, Department of Immunology, School of Medicine, University of
 Tromso, N-9037 Tromso, Norway.
 E-mail: kristian.hannestad@fagmed.uit.no
 SO Proceedings of the National Academy of Sciences of the United States of
 America, (28 MAY 2002), 99/11 (7588-7593), 49 reference(s)
 CODEN: PNASA6 ISSN: 0027-8424
 DT Journal; Article
 CY United States
 LA English
 SL English

L4 ANSWER 78 OF 201 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:78268 CAPLUS
 DN 134:146376
 TI Fc fusion proteins for enhancing the immunogenicity of protein and peptide
 antigens
 IN Gillies, Stephen D.; Lo, Kin Ming; Wesolowski, John S., Jr.
 PA Lexigen Pharmaceuticals Corp., USA
 SO PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007081	A1	20010201	WO 2000-US19816	20000721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2378866	AA	20010201	CA 2000-2378866	20000721
EP 1198250	A1	20020424	EP 2000-950483	20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000012569	A	20020528	BR 2000-12569	20000721
JP 2003505431	T2	20030212	JP 2001-511964	20000721
NO 2002000255	A	20020315	NO 2002-255	20020117
ZA 2002000501	A	20030121	ZA 2002-501	20020121
PRAI US 1999-144965P	P	19990721		
WO 2000-US19816	W	20000721		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 79 OF 201 USPATFULL on STN
AN 2001:176635 USPATFULL
TI Icam-related protein
IN Gallatin, W. Michael, Mercer Island, WA, United States
Vazeux, Rosemay, Seattle, WA, United States
PA ICOS Corporation (U.S. corporation)
PI US 2001029293 A1 20011011
AI US 2001-753436 A1 20010103 (9)
RLI Continuation of Ser. No. US 1999-382289, filed on 24 Aug 1999, ABANDONED
Continuation-in-part of Ser. No. US 1995-487113, filed on 7 Jun 1995,
GRANTED, Pat. No. US 5837822 Continuation-in-part of Ser. No. US
1993-102852, filed on 5 Aug 1993, ABANDONED Continuation-in-part of Ser.
No. US 1993-9266, filed on 22 Jan 1993, ABANDONED Continuation-in-part
of Ser. No. WO 1993-US787, filed on 26 Jan 1993, UNKNOWN
Continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,
ABANDONED Continuation-in-part of Ser. No. US 1992-889724, filed on 26
May 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-827689,
filed on 27 Jan 1992, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 7122
INCL INCLM: 530/387.300
INCLS: 435/007.920
NCL NCLM: 530/387.300
NCLS: 435/007.920
IC [7]
ICM: G01N033-537
ICS: G01N033-543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 80 OF 201 USPATFULL on STN
AN 2001:185455 USPATFULL
TI Cytokine zalphall Ligand
IN Novak, Julia E., Bainbridge Island, WA, United States
Presnell, Scott R., Tacoma, WA, United States
Sprecher, Cindy A., Seattle, WA, United States
Foster, Donald C., Lake Forest Park, WA, United States
Holly, Richard D., Seattle, WA, United States
Gross, Jane A., Seattle, WA, United States
Johnston, Janet V., Seattle, WA, United States
Nelson, Andrew J., Shoreline, WA, United States
Dillon, Stacey R., Seattle, WA, United States
Hammond, Angela K., Maple Valley, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6307024 B1 20011023
AI US 2000-522217 20000309 (9)
PRAI US 1999-123547P 19990309 (60)
US 1999-123904P 19990311 (60)
US 1999-142013P 19990701 (60)
DT Utility
FS GRANTED
LN.CNT 7160
INCL INCLM: 530/351.000
INCLS: 530/350.000; 435/069.100; 435/069.700; 424/143.100; 424/145.100
NCL NCLM: 530/351.000
NCLS: 424/143.100; 424/145.100; 435/069.100; 435/069.700; 530/350.000
IC [7]
ICM: C07K014-00
ICS: C12P021-06; C12P021-04; A61K039-395
EXF 530/380; 530/351; 435/69.1; 435/69.7; 424/143.1; 424/145.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 81 OF 201 USPATFULL on STN
AN 2001:131067 USPATFULL
TI Methods for the preparation of positively charged proteins
IN Grinna, Lynn, Middleburg, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 6274348 B1 20010814
AI US 1997-885366 19970630 (8)
RLI Continuation of Ser. No. US 1993-64693, filed on 19 May 1993, now
patented, Pat. No. US 5643570 Continuation-in-part of Ser. No. US
1992-885911, filed on 19 May 1992, now abandoned
DT Utility
FS GRANTED
LN.CNT 1361
INCL INCLM: 435/071.100

NCL INCLS: 435/383.000; 435/395.000; 435/404.000; 530/350.000
NCLM: 435/071.100
NCLS: 435/383.000; 435/395.000; 435/404.000; 530/350.000
IC [7]
ICM: C12P021-00
ICS: C12N005-02; C12N005-00; C07K001-02
EXF 435/71; 435/71.1; 435/383; 435/395; 435/404; 530/350; 530/402; 530/403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 82 OF 201 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2001-316421 [33] WPIDS
DNN N2001-227440 DNC C2001-097519
TI Modifying antibody useful in therapeutics, involves recombining first
polynucleotide or character string encoding antibody with second
polynucleotide or character string to produce library of modified
antibodies.
DC B04 D16 T01
IN BASS, S H; KARRER, E; PATTEN, P A; WHALEN, R
PA (MAXY-N) MAXYGEN INC
CYC 95
PI WO 2001032712 A2 20010510 (200133)* EN 109 C07K016-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2001014561 A 20010514 (200149) C07K016-00
EP 1230269 A2 20020814 (200261) EN C07K016-00
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR
ADT WO 2001032712 A2 WO 2000-US30247 20001101; AU 2001014561 A AU 2001-14561
20001101; EP 1230269 A2 EP 2000-976844 20001101, WO 2000-US30247 20001101
FDT AU 2001014561 A Based on WO 2001032712; EP 1230269 A2 Based on WO
2001032712
PRAI US 2000-176002P 20000112; US 1999-163370P 19991103
IC ICM C07K016-00
ICS A61K039-21; A61K039-42; C07K014-16; C07K016-10; C07K016-12;
C07K016-46; C12N001-21; C12N015-13; C12N015-49; C12N015-62;
G06F017-30

L4 ANSWER 83 OF 201 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2001-191523 [19] WPIDS
DNC C2001-057409
TI Novel multifunctional fusion protein or protein complexes useful for
treating cancer and viral infections, comprise two different cytokine
molecules and a targeting group.
DC B04 D16
IN GILLIES, S D; LO, K M; LO, K
PA (LEXI-N) LEXIGEN PHARM CORP; (GILL-I) GILLIES S D; (LOKK-I) LO K; (EMDL-N)
EMD LEXIGEN RES CENT CORP
CYC 95
PI WO 2001010912 A1 20010215 (200119)* EN 59 C07K019-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
AU 2000066268 A 20010305 (200130) C07K019-00
EP 1200479 A1 20020502 (200236) EN C07K019-00
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
NO 2002000641 A 20020408 (200236) C07K000-00
BR 2000013231 A 20020723 (200257) C07K019-00
KR 2002026368 A 20020409 (200267) C07K019-00
CZ 2002000389 A3 20021211 (200309) C07K019-00
HU 2002002442 A2 20021128 (200309) C07K019-00
JP 2003507012 W 20030225 (200317) 111 C12N015-09
CN 1382158 A 20021127 (200322) C07K019-00
ZA 2002000789 A 20030326 (200327) 106 C07K000-00
US 6617135 B1 20030909 (200361) C12N015-62
SK 2002000184 A3 20030911 (200363) C07K019-00
MX 2002001417 A1 20020801 (200367) A61K038-20
US 2004072299 A1 20040415 (200426) C07K016-46
ADT WO 2001010912 A1 WO 2000-US21715 20000809; AU 2000066268 A AU 2000-66268

20000809; EP 1200479 A1 EP 2000-953896 20000809, WO 2000-US21715 20000809;
NO 2002000641 A WO 2000-US21715 20000809, NO 2002-641 20020208; BR
2000013231 A BR 2000-13231 20000809, WO 2000-US21715 20000809; KR
2002026368 A KR 2002-701705 20020207; CZ 2002000389 A3 WO 2000-US21715
20000809, CZ 2002-389 20000809; HU 2002002442 A2 WO 2000-US21715 20000809,
HU 2002-2442 20000809; JP 2003507012 W WO 2000-US21715 20000809, JP
2001-515719 20000809; CN 1382158 A CN 2000-813726 20000809; ZA 2002000789
A ZA 2002-789 20020129; US 6617135 B1 Provisional US 1999-147924P
19990809, US 2000-634368 20000809; SK 2002000184 A3 WO 2000-US21715
20000809, SK 2002-184 20000809; MX 2002001417 A1 WO 2000-US21715 20000809,
MX 2002-1417 20020208; US 2004072299 A1 Provisional US 1999-147924P
19990809, Cont of US 2000-634368 20000809, US 2003-603064 20030624
FDT AU 2000066268 A Based on WO 2001010912; EP 1200479 A1 Based on WO
2001010912; BR 2000013231 A Based on WO 2001010912; CZ 2002000389 A3 Based
on WO 2001010912; HU 2002002442 A2 Based on WO 2001010912; JP 2003507012 W
Based on WO 2001010912; SK 2002000184 A3 Based on WO 2001010912; MX
2002001417 A1 Based on WO 2001010912; US 2004072299 A1 Cont of US 6617135
PRAI US 1999-147924P 19990809; US 2000-634368 20000809;
US 2003-603064 20030624
IC ICM A61K038-20; C07K000-00; C07K016-46; C07K019-00; C12N015-09;
C12N015-62
ICS A61K031-7088; A61K035-12; A61K038-00; A61K039-395; A61K048-00;
A61P031-12; A61P035-00; A61P037-04; C07K014-53; C07K016-08;
C07K016-32; C12N001-15; C12N001-19; C12N001-21; C12N005-10;
C12N015-63; C12P021-02
ICA C07K014-52; C07K014-535; C07K014-54; C07K014-55; C07K016-30
ICI C07K014:52, C07K014:535, C07K014:54, C07K014:55, C07K016-30

L4 ANSWER 84 OF 201 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN
AN 2001:813180 SCISEARCH
GA The Genuine Article (R) Number: 480WE
TI In situ class switching and differentiation to IgA-producing cells in the
gut lamina propria
AU Fagarasan S; Kinoshita K; Muramatsu M; Ikuta K; Honjo T (Reprint)
CS Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Yoshida Konoe Cho,
Kyoto 6068501, Japan (Reprint); Kyoto Univ, Grad Sch Med, Dept Med Chem,
Sakyo Ku, Kyoto 6068501, Japan
CYA Japan
SO NATURE, (11 OCT 2001) Vol. 413, No. 6856, pp. 639-643.
Publisher: MACMILLAN PUBLISHERS LTD, PORTERS SOUTH, 4 CRINAN ST, LONDON N1
9XW, ENGLAND.
ISSN: 0028-0836.
DT Article; Journal
LA English
REC Reference Count: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 85 OF 201 USPATFULL on STN
AN 2000:141878 USPATFULL
TI Recombinant anti-CD4 antibodies for human therapy
IN Hanna, Nabil, Olivenhain, CA, United States
Newman, Roland Anthony, San Diego, CA, United States
Reff, Mitchell Elliot, San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
PI US 6136310 20001024
AI US 1995-523894 19950906 (8)
RLI Continuation-in-part of Ser. No. US 1995-476237, filed on 7 Jun 1995,
now patented, Pat. No. US 5756096 which is a continuation-in-part of
Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US
5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10
Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US
1992-856281, filed on 23 Mar 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991,
now abandoned
DT Utility
FS Granted
LN.CNT 3398
INCL INCLM: 424/154.100
INCLS: 530/387.300; 424/133.100; 424/141.100
NCL NCLM: 424/154.100
NCLS: 424/133.100; 424/141.100; 530/387.300
IC [7]
ICM: A61K039-395
ICS: C12P021-08

EXF 530/387.3; 424/133.1; 424/141.1; 424/154.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 86 OF 201 USPATFULL on STN
AN 2000:102415 USPATFULL
TI Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
IN Gallatin, W. Michael, Seattle, WA, United States
Vazeux, Rosemay, Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 6100383 20000808
AI US 1995-475680 19950607 (8)
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now abandoned And a continuation-in-part of Ser. No. WO 1993-US787, filed on 26 Jan 1993 which is a continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992, now abandoned
DT Utility
FS Granted
LN.CNT 6203
INCL INCLM: 530/387.300
INCLS: 530/300.000; 530/350.000; 435/069.700
NCL NCLM: 530/387.300
NCLS: 435/069.700; 530/300.000; 530/350.000
IC [7]
ICM: C12P021-08
EXF 530/387.3; 530/388.2; 530/300; 530/350; 424/134.1; 424/133.1; 435/69.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 87 OF 201 USPATFULL on STN
AN 2000:98222 USPATFULL
TI Cells with multiple altered epitopes on a surface antigen for use in transplantation
IN Chappel, Scott C., Milton, MA, United States
PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
PI US 6096537 20000801
AI US 1997-946637 19971007 (8)
RLI Continuation of Ser. No. US 1994-240150, filed on 10 May 1994, now patented, Pat. No. US 5679340 which is a continuation-in-part of Ser. No. US 1994-220741, filed on 31 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 940
INCL INCLM: 435/325.000
INCLS: 424/422.000; 424/133.100; 424/143.100; 424/093.700; 435/007.100; 435/007.200; 435/007.210; 530/388.220
NCL NCLM: 435/325.000
NCLS: 424/093.700; 424/133.100; 424/143.100; 424/422.000; 435/007.100; 435/007.200; 435/007.210; 530/388.220
IC [7]
ICM: C12N005-00
ICS: A61F013-00; G01N033-53; C07K016-00
EXF 424/93.7; 424/422; 424/133.1; 424/143.1; 435/325; 435/7.1; 435/7.2; 435/7.21; 530/388.22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 88 OF 201 USPATFULL on STN
AN 2000:84089 USPATFULL
TI Antibodies which specifically bind to a novel .kappa./.mu.-like protein tyrosineospatase, PTP.lambda., and hybridoma cell lines producing the same
IN Cheng, Jill, Burlingame, CA, United States
Lasky, Laurence A., Sausalito, CA, United States
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)
PI US 6083748 20000704
AI US 1997-991953 19971216 (8)
RLI Division of Ser. No. US 1996-652971, filed on 24 May 1996, now patented, Pat. No. US 5814507, issued on 29 Sep 1998
DT Utility
FS Granted
LN.CNT 3514

INCL INCLM: 435/338.000
INCLS: 435/331.000; 435/334.000; 530/388.100; 530/388.220; 530/388.260
NCL NCLM: 435/338.000
NCLS: 435/331.000; 435/334.000; 530/388.100; 530/388.220; 530/388.260
IC [7]
ICM: C07K016-00
ICS: C12N005-12
EXF 530/387.1; 530/387.3; 530/387.9; 530/388.26; 530/388.1; 530/389.1;
530/391.1; 530/388.22; 435/331; 435/334; 435/338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 89 OF 201 USPATFULL on STN
AN 2000:34422 USPATFULL
TI Antibodies to ICAM-related protein
IN Gallatin, W. Michael, Seattle, WA, United States
Vazeux, Rosemay, Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 6040176 20000321
AI US 1996-714017 19960912 (8)
RLI Continuation of Ser. No. US 1994-286754, filed on 5 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US787, filed on 26 Jan 1993 which is a continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992, now abandoned
DT Utility
FS Granted
LN.CNT 6171
INCL INCLM: 435/326.000
INCLS: 530/388.100
NCL NCLM: 435/326.000
NCLS: 530/388.100
IC [7]
ICM: C12N005-00
ICS: C07K016-00; C12P021-08
EXF 530/388.1; 530/388.22; 435/326
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 90 OF 201 USPATFULL on STN
AN 1999:163215 USPATFULL
TI Humanized antibodies to human gp39, compositions containing thereof
IN Black, Amelia, Cardiff, CA, United States
Hanna, Nabil, Olivenhian, CA, United States
Padlan, Eduardo A., Kensington, MD, United States
Newman, Roland A., San Diego, CA, United States
PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 6001358 19991214
AI US 1995-554840 19951107 (8)
DT Utility
FS Granted
LN.CNT 2693
INCL INCLM: 424/154.100
INCLS: 424/130.100; 424/133.100; 424/144.100; 424/143.100; 424/153.100;
424/154.100; 424/173.100; 424/141.100; 530/387.100; 530/387.300;
530/388.100; 530/388.200; 530/388.220; 530/388.700; 530/388.730;
530/388.750; 536/023.530
NCL NCLM: 424/154.100
NCLS: 424/130.100; 424/133.100; 424/141.100; 424/143.100; 424/144.100;
424/153.100; 424/173.100; 530/387.100; 530/387.300; 530/388.100;
530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750;
536/023.530
IC [6]
ICM: A61K039-395
ICS: C07K016-28
EXF 424/130.1; 424/133.1; 424/141.1; 424/143.1; 424/144.1; 424/154.1;
424/173.1; 424/153.1; 435/69.6; 435/70.21; 435/320.1; 435/172.2;
435/172.3; 530/387.3; 530/388.22; 530/388.75; 530/388.2; 530/388.7;
530/388.73; 530/388.1; 530/387.1; 536/23.53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 91 OF 201 USPATFULL on STN

AN 1999:150946 USPATFULL
 TI Methods for identifying modulators of protein kinase C phosphorylation
 of ICAM-related protein
 IN Gallatin, W. Michael, Mercer Island, WA, United States
 Vazeux, Rosemay, Seattle, WA, United States
 PA ICOS Corporation, Bothwell, WA, United States (U.S. corporation)
 PI US 5989843 19991123
 AI US 1996-720420 19960927 (8)
 RLI Continuation-in-part of Ser. No. US 1995-487113, filed on 7 Jun 1995,
 now patented, Pat. No. US 5837822 which is a continuation-in-part of
 Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a
 continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now
 abandoned And Ser. No. WO 1993-US787, filed on 26 Jan 1993 which is a
 continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,
 now abandoned which is a continuation-in-part of Ser. No. US
 1992-889724, filed on 26 May 1992 which is a continuation-in-part of
 Ser. No. US 1992-827689, filed on 27 Jan 1992
 DT Utility
 FS Granted
 LN.CNT 7311
 INCL INCLM: 435/015.000
 INCLS: 435/004.000
 NCL NCLM: 435/015.000
 NCLS: 435/004.000
 IC [6]
 ICM: C12Q001-48
 EXF 435/4; 435/7.1; 435/7.2; 435/15; 436/518; 450/300; 450/324; 450/344;
 450/345; 450/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 92 OF 201 USPATFULL on STN
 AN 1999:146315 USPATFULL
 TI Directed switch-mediated DNA recombination
 IN Jakobovits, Aya, Menlo Park, CA, United States
 Gallo, Michael Lajos, San Jose, CA, United States
 Yang, Xiao-Ping, Foster City, CA, United States
 PA Abgenix, Inc., Fremont, CA, United States (U.S. corporation)
 Japan Tobacco Inc., Tokyo, Japan (non-U.S. corporation)
 PI US 5985615 19991116
 AI US 1997-878166 19970617 (8)
 RLI Continuation of Ser. No. US 1996-619109, filed on 20 Mar 1996, now
 patented, Pat. No. US 5714352
 DT Utility
 FS Granted
 LN.CNT 1492
 INCL INCLM: 435/069.600
 INCLS: 435/252.300; 435/325.000; 435/328.000; 435/355.000; 435/372.200;
 435/463.000
 NCL NCLM: 435/069.600
 NCLS: 435/252.300; 435/325.000; 435/328.000; 435/355.000; 435/372.200;
 435/463.000
 IC [6]
 ICM: C12N001-21
 ICS: C12N005-10; C12N005-20; C12N015-00
 EXF 536/23.1; 536/23.53; 435/69.1; 435/70.21; 435/172.3; 435/320.1; 435/325;
 435/326; 435/328; 435/372.3; 435/252.3; 435/69.6; 435/463; 435/372.2;
 435/355
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 93 OF 201 USPATFULL on STN
 AN 1999:137001 USPATFULL
 TI K.kappa./mu.-like protein tyrosine phosphatase, PTP .lambda.
 IN Cheng, Jill, Burlingame, CA, United States
 Lasky, Laurence A., Saulito, CA, United States
 PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)
 PI US 5976852 19991102
 AI US 1996-769399 19961219 (8)
 RLI Division of Ser. No. US 1996-652971, filed on 24 May 1996, now patented,
 Pat. No. US 5814507
 DT Utility
 FS Granted
 LN.CNT 3522
 INCL INCLM: 435/196.000
 INCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.200; 935/022.000
 NCL NCLM: 435/196.000
 NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.200

IC [6]
ICM: C12N009-16
ICS: C12N001-20; C12N005-00; C07H021-04
EXF 435/240.2; 435/252.3; 435/320.1; 435/196; 435/325; 536/23.2; 935/22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 94 OF 201 USPATFULL on STN
AN 1999:117748 USPATFULL
TI Transgenic plants expressing assembled secretory antibodies
IN Hein, Mich B., Fallbrook, CA, United States
Hiatt, Andrew, San Diego, CA, United States
Ma, Julian K-C, London, United Kingdom
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5959177 19990928
AI US 1996-642406 19960503 (8)
RLI Continuation-in-part of Ser. No. US 1992-971951, filed on 5 Nov 1992, now patented, Pat. No. US 5639947 which is a continuation of Ser. No. US 1990-591823, filed on 2 Oct 1990, now patented, Pat. No. US 5202422 which is a continuation-in-part of Ser. No. US 1989-427765, filed on 27 Oct 1989, now abandoned
DT Utility
FS Granted
LN.CNT 4721
INCL INCLM: 800/288.000
INCLS: 800/295.000; 435/419.000; 435/069.100; 435/320.100; 536/023.500; 536/023.530; 536/024.100
NCL NCLM: 800/288.000
NCLS: 435/069.100; 435/320.100; 435/419.000; 536/023.500; 536/023.530; 536/024.100; 800/295.000

IC [6]
ICM: C12N015-00
ICS: C12N015-29; C12N015-82; A01H005-00
EXF 800/209; 435/172.3; 435/320.1; 435/419; 435/69.1; 536/23.5; 536/25.53; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 95 OF 201 USPATFULL on STN
AN 1999:85238 USPATFULL
TI .kappa./mu.-Like protein tyrosine phosphatase, PTP .lambda.
IN Cheng, Jill, Burlingame, CA, United States
Lasky, Laurence A., Saulito, CA, United States
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)
PI US 5928887 19990727
AI US 1997-991258 19971216 (8)
RLI Division of Ser. No. US 1996-652971, filed on 24 May 1996, now patented, Pat. No. US 5814507
DT Utility
FS Granted
LN.CNT 3235
INCL INCLM: 435/021.000
INCLS: 435/196.000; 536/023.200
NCL NCLM: 435/021.000
NCLS: 435/196.000; 536/023.200
IC [6]
ICM: C12Q001-42
ICS: C12N009-16; C07H021-04
EXF 435/21; 435/196; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 96 OF 201 USPATFULL on STN
AN 1999:30947 USPATFULL
TI Modulators of the interaction between ICAM-R and .alpha..sub.d /CD18
IN Gallatin, W. Michael, Seattle, WA, United States
Vazeux, Rosemay, Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 5880268 19990309
AI US 1995-483932 19950607 (8)
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992,

now abandoned
DT Utility
FS Granted
LN.CNT 5823
INCL INCLM: 530/387.300
INCLS: 530/387.900; 530/388.100; 530/388.220
NCL NCLM: 530/387.300
NCLS: 530/387.900; 530/388.100; 530/388.220
IC [6]
ICM: C12P021-08
ICS: C07K016-00
EXF 530/300; 530/350; 530/387.1; 530/387.9; 530/388.1; 530/388.22;
530/388.25; 530/388.7; 530/388.73; 530/388.75; 530/389.1; 530/389.6;
530/387.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 97 OF 201 USPATFULL on STN
AN 1999:18933 USPATFULL
TI Method for monitoring an inflammatory disease state by detecting
circulating ICAM-R
IN Gallatin, W. Michael, Seattle, WA, United States
Vazeux, Rosemay, Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 5869262 19990209
AI US 1995-473503 19950607 (8)
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994, now abandoned
which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5
Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US
1993-9266, filed on 22 Jan 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,
now abandoned which is a continuation-in-part of Ser. No. US
1992-889724, filed on 26 May 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992,
now abandoned

DT Utility
FS Granted
LN.CNT 5859
INCL INCLM: 435/007.100
INCLS: 435/007.920; 435/007.940; 435/007.950; 436/811.000
NCL NCLM: 435/007.100
NCLS: 435/007.920; 435/007.940; 435/007.950; 436/811.000
IC [6]
ICM: G01N033-53
EXF 424/131.1; 424/9; 424/142.1; 424/144.1; 436/86; 436/811; 435/7.1;
435/7.92; 435/7.94; 435/7.95; 530/388.2; 530/388.22

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 98 OF 201 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:799445 CAPLUS
DN 132:92211
TI High pathogenic potential of low-affinity autoantibodies in experimental
autoimmune hemolytic anemia
AU Fossati-Jimack, Liliane; Reiningier, Luc; Chicheportiche, Yves; Clynes,
Raphael; Ravetch, Jeffrey V.; Honjo, Tasuku; Izui, Shozo
CS Department of Pathology, University of Geneva, Geneva, 1211/4, Switz.
SO Journal of Experimental Medicine (1999), 190(11), 1689-1696
CODEN: JEMEAV; ISSN: 0022-1007
PB Rockefeller University Press
DT Journal
LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 99 OF 201 USPATFULL on STN
AN 1998:144218 USPATFULL
TI Humanized antibodies specific for ICAM related protein
IN Gallatin, W. Michael, Seattle, WA, United States
Vazeux, Rosemay, Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 5837822 19981117
AI US 1995-487113 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993,
now abandoned which is a continuation-in-part of Ser. No. US 1993-9266,
filed on 22 Jan 1993, now abandoned which is a continuation-in-part of
Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992,

now abandoned which is a continuation-in-part of Ser. No. US
1992-827689, filed on 27 Jan 1992, now abandoned

DT Utility
FS Granted
LN.CNT 6796
INCL INCLM: 530/387.300
INCLS: 530/388.100; 530/388.220
NCL NCLM: 530/387.300
NCLS: 530/388.100; 530/388.220
IC [6]
ICM: C12P021-08
EXF 530/387.1; 530/387.3; 530/388.1; 530/388.22; 530/867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 100 OF 201 USPATFULL on STN
AN 1998:119029 USPATFULL
TI .kappa./mu.-like protein tyrosine phosphatase, PTP .lambda.
IN Cheng, Jill, Burlingame, CA, United States
Lasky, Laurence A., Saulito, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5814507 19980929
AI US 1996-652971 19960524 (8)
DT Utility
FS Granted
LN.CNT 2996
INCL INCLM: 435/196.000
INCLS: 530/387.300
NCL NCLM: 435/196.000
NCLS: 530/387.300
IC [6]
ICM: C12N009-16
ICS: C12P021-08
EXF 435/196; 530/387.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 101 OF 201 USPATFULL on STN
AN 1998:115830 USPATFULL
TI ICAM-related protein variants
IN Gallatin, W. Michael, Seattle, WA, United States
Vazeux, Rosemay, Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 5811517 19980922
AI US 1995-483389 19950607 (8)
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994, now abandoned
which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5
Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US
1993-9266, filed on 2 Dec 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1992-894061, filed on 5 Jun 1992,
now abandoned which is a continuation-in-part of Ser. No. US
1992-889724, filed on 26 May 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 5991
INCL INCLM: 530/350.000
INCLS: 536/023.400; 536/023.100; 435/069.100; 435/069.700; 435/320.100;
435/325.000; 435/252.300
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 435/325.000;
536/023.100; 536/023.400
IC [6]
ICM: C07K019-00
ICS: C12N015-62
EXF 536/23.5; 536/23.1; 530/350; 530/395; 435/69.1; 435/69.7; 435/252.3;
435/320.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 102 OF 201 USPATFULL on STN
AN 1998:75369 USPATFULL
TI Method to identify compounds which modulate ICAM-related protein
interactions
IN Gallatin, W. Michael, Seattle, WA, United States
Vazeux, Rosemay, Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)

PI US 5773218 19980630
AI US 1995-482882 19950607 (8)
RLI Division of Ser. No. US 1994-286754, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 1993-102852, filed on 5 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-9266, filed on 22 Jan 1993, now abandoned And Ser. No. US 1992-894061, filed on 5 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-889724, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-827689, filed on 27 Jan 1992, now abandoned
DT Utility
FS Granted
LN.CNT 5498
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [6]
ICM: C12Q001-68
EXF 435/6; 435/7.2; 435/69.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 103 OF 201 USPATFULL on STN
AN 1998:57523 USPATFULL
TI Recombinant antibodies for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5756096 19980526
AI US 1995-476237 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US 5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1919
INCL INCLM: 424/154.100
INCLS: 424/133.100; 424/141.100; 530/387.100
NCL NCLM: 424/154.100
NCLS: 424/133.100; 424/141.100; 530/387.100
IC [6]
ICM: A61K039-395
EXF 424/133.1; 424/141.1; 424/154.1; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 104 OF 201 USPATFULL on STN
AN 1998:51191 USPATFULL
TI Recombinant antibodies for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5750105 19980512
AI US 1995-476349 19950607 (8)
RLI Division of Ser. No. US 1995-379072, filed on 5 Dec 1995 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
FS Granted
LN.CNT 2110
INCL INCLM: 424/133.100
INCLS: 424/177.100; 424/137.100; 424/138.100; 530/387.300
NCL NCLM: 424/133.100
NCLS: 424/137.100; 424/138.100; 424/177.100; 530/387.300
IC [6]
ICM: A61K039-395
ICS: A61K039-40; A61K039-42; C12P021-08
EXF 424/130.1; 424/133.1; 424/177.1; 424/137.1; 424/138.1; 530/387.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 105 OF 201 USPATFULL on STN
AN 1998:25104 USPATFULL
TI Expression and export technology of proteins as immunofusins
IN Lo, Kin-Ming, Wellesley, MA, United States
Sudo, Yukio, Lexington, MA, United States
Gillies, Stephen D., Carlisle, MA, United States
PA Fuji ImmunoPharmaceuticals Corp., Lexington, MA, United States (U.S. corporation)
PI US 5726044 19980310
AI US 1995-528122 19950914 (8)
RLI Continuation-in-part of Ser. No. US 1994-305700, filed on 14 Sep 1994, now patented, Pat. No. US 5541087
DT Utility
FS Granted
LN.CNT 1312
INCL INCLM: 435/069.700
INCLS: 435/069.800; 435/070.100; 435/320.100; 435/328.000; 536/023.530
NCL NCLM: 435/069.700
NCLS: 435/069.800; 435/070.100; 435/320.100; 435/328.000; 536/023.530
IC [6]
ICM: C07K016-46
ICS: C12N015-13; C12N015-11
EXF 536/23.5; 536/23.53; 435/320.1; 435/328; 435/69.7; 435/69.8; 435/70.1; 435/69.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 106 OF 201 USPATFULL on STN
AN 1998:11898 USPATFULL
TI Directed switch-mediated DNA recombination
IN Jakobovits, Aya, Menlo Park, CA, United States
PA Xenotech Incorporated, Foster City, CA, United States (U.S. corporation)
PI US 5714352 19980203
AI US 1996-619109 19960320 (8)
DT Utility
FS Granted
LN.CNT 1450
INCL INCLM: 435/172.300
INCLS: 435/320.100; 435/328.000; 435/372.300
NCL NCLM: 435/462.000
NCLS: 435/320.100; 435/328.000; 435/372.300
IC [6]
ICM: C12N015-63
ICS: C12N015-79; C12N005-08; C12N005-24
EXF 435/69.1; 435/70.21; 435/172.3; 435/320.1; 435/325; 435/326; 435/328; 435/372.3; 536/23.1; 536/23.53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 107 OF 201 USPATFULL on STN
AN 97:112606 USPATFULL
TI Recombinant antibodies for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5693780 19971202
AI US 1995-481869 19950607 (8)
RLI Division of Ser. No. US 1995-379072, filed on 25 Jan 1995 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1755
INCL INCLM: 536/023.530
INCLS: 435/252.300; 435/320.100
NCL NCLM: 536/023.530
NCLS: 435/252.300; 435/320.100
IC [6]
ICM: C07H021-04
ICS: C12N001-20; C12N015-00
EXF 536/23.53; 435/320.1; 435/252.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 108 OF 201 USPATFULL on STN

AN 97:99175 USPATFULL
TI Recombinant antibodies for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5681722 19971028
AI US 1995-478039 19950607 (8)
RLI Division of Ser. No. US 1995-379072, filed on 25 Jan 1995 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
FS Granted
LN.CNT 2117
INCL INCLM: 435/069.700
INCLS: 536/023.530; 536/024.320; 435/069.700; 435/091.200; 435/006.000; 530/387.300
NCL NCLM: 435/069.700
NCLS: 435/006.000; 435/091.200; 530/387.300; 536/023.530; 536/024.330
IC [6]
ICM: C12P021-08
ICS: C12P021-04; C12P019-34; C07H021-04
EXF 536/23.53; 536/24.33; 435/6; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 109 OF 201 USPATFULL on STN
AN 97:96549 USPATFULL
TI Cells with multiple altered epitopes on a surface antigen for use in transplantation
IN Chappel, Scott C., Milton, MA, United States
PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
PI US 5679340 19971021
AI US 1994-240150 19940510 (8)
RLI Continuation-in-part of Ser. No. US 1994-220741, filed on 31 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 994
INCL INCLM: 424/093.100
INCLS: 435/240.200
NCL NCLM: 424/093.100
NCLS: 435/325.000; 435/366.000; 435/368.000; 435/370.000; 435/371.000; 435/372.000
IC [6]
ICM: C12N005-00
ICS: A01N063-00
EXF 424/93.1; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 110 OF 201 USPATFULL on STN
AN 97:73287 USPATFULL
TI Recombinant antibodies for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5658570 19970819
AI US 1995-379072 19950125 (8)
RLI Continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1829
INCL INCLM: 424/184.100
INCLS: 530/388.220; 435/070.210; 435/172.200; 435/172.300; 435/069.600; 935/096.000
NCL NCLM: 424/184.100
NCLS: 435/069.600; 435/070.210; 530/388.220
IC [6]
ICM: C07K016-28

ICS: A61K039-38; C12P021-04
EXF 424/184.1; 530/388.22; 435/69.6; 435/70.21; 435/172.2; 435/172.3; 935/96
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 111 OF 201 USPATFULL on STN
AN 97:56338 USPATFULL
TI BPI-immunoglobulin fusion proteins
IN Theofan, Georgia, Torrance, CA, United States
Grinna, Lynn S., Middleburg, VA, United States
Horwitz, Arnold, Los Angeles, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5643570 19970701
AI US 1993-64693 19930519 (8)
RLI Continuation-in-part of Ser. No. US 1992-885911, filed on 19 May 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 1593
INCL INCLM: 424/134.100
INCLS: 435/252.300; 435/172.300; 435/320.100; 435/069.100; 530/387.300;
536/023.400
NCL NCLM: 424/134.100
NCLS: 435/069.100; 435/252.300; 435/320.100; 530/387.300; 536/023.400
IC [6]
ICM: C12N015-12
ICS: C12N015-00; A61K039-395; C07K019-00
EXF 530/387.3; 435/240.2; 435/252.3; 435/69.1; 435/172.3; 435/320.1;
424/85.8; 424/134.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 112 OF 201 USPATFULL on STN
AN 96:103888 USPATFULL
TI CD27 ligand
IN Beckmann, M. Patricia, Poulsbo, WA, United States
Goodwin, Raymond G., Seattle, WA, United States
Giri, Judith G., Seattle, WA, United States
Armitage, Richard J., Bainbridge Island, WA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5573924 19961112
AI US 1993-106507 19930813 (8)
RLI Continuation-in-part of Ser. No. US 1992-941648, filed on 8 Sep 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 1789
INCL INCLM: 435/069.500
INCLS: 435/240.200; 435/252.000; 435/003.000; 435/320.100; 530/351.000;
536/023.500; 930/140.000
NCL NCLM: 435/069.500
NCLS: 435/252.300; 435/320.100; 435/365.100; 530/351.000; 536/023.500;
930/140.000
IC [6]
ICM: C12N015-19
ICS: C07K014-52
EXF 530/350; 530/351; 530/403; 530/399; 536/23.5; 435/69.3; 435/69.5X;
435/240.1; 435/240.2; 435/252.3; 435/320.1; 930/140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 113 OF 201 USPATFULL on STN
AN 96:67909 USPATFULL
TI Expression and export technology of proteins as immunofusins
IN Lo, Kin-Ming, Wellesley, MA, United States
Sudo, Yukio, Lexington, MA, United States
Gillies, Stephen D., Hingham, MA, United States
PA Fuji Immunopharmaceuticals Corporation, Lexington, MA, United States
(U.S. corporation)
PI US 5541087 19960730
AI US 1994-305700 19940914 (8)
DT Utility
FS Granted
LN.CNT 1142
INCL INCLM: 435/697.000
INCLS: 435/069.800; 435/070.100; 435/240.100; 435/252.300; 435/320.100;
530/387.300; 530/391.100; 530/391.700; 530/402.000; 530/344.000;
530/345.000; 536/023.100; 536/023.400; 536/023.530
NCL NCLM: 435/069.700

NCLS: 435/069.800; 435/070.100; 435/252.300; 435/320.100; 435/355.000;
435/369.000; 530/344.000; 530/345.000; 530/387.300; 530/391.100;
530/391.700; 530/402.000; 536/023.100; 536/023.400; 536/023.530

IC [6]

ICM: C07K016-46

ICS: C12N015-13; C12N015-11

EXF 435/69.7; 435/69.8; 435/70.1; 435/240.1; 435/252.3; 435/320.1;
530/387.3; 530/387.1; 530/391.1; 530/866; 530/867; 530/402; 530/344;
530/345; 530/391.7; 530/23.53; 530/23.1; 530/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 114 OF 201 USPATFULL on STN

AN 96:38806 USPATFULL

TI Recombinant DNA encoding hybrid immunoglobulins

IN Capon, Daniel J., San Mateo, CA, United States

Lasky, Laurence A., Sausalito, CA, United States

PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

PI US 5514582 19960507

AI US 1994-185670 19940121 (8)

RLI Continuation of Ser. No. US 1992-986931, filed on 8 Dec 1992, now
patented, Pat. No. US 5428130 which is a continuation of Ser. No. US
1991-808122, filed on 16 Dec 1991, now patented, Pat. No. US 5225538
which is a division of Ser. No. US 1989-440625, filed on 22 Nov 1989,
now patented, Pat. No. US 5116964 which is a continuation-in-part of
Ser. No. US 1989-315015, filed on 23 Feb 1989, now patented, Pat. No. US
5098833

DT Utility

FS Granted

LN.CNT 2644

INCL INCLM: 435/252.300

INCLS: 435/069.700; 435/320.100; 536/023.500; 536/023.520; 536/023.530

NCL NCLM: 435/252.300

NCLS: 435/069.700; 435/320.100; 536/023.500; 536/023.520; 536/023.530

IC [6]

ICM: C12N015-62

EXF 435/69.7; 435/252.3; 435/320.1; 536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 115 OF 201 USPATFULL on STN

AN 95:58232 USPATFULL

TI Hybrid immunoglobulins

IN Capon, Daniel J., San Mateo, CA, United States

Lasky, Laurence A., Sausalito, CA, United States

PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

PI US 5428130 19950627

AI US 1992-986931 19921208 (7)

RLI Continuation of Ser. No. US 1991-808122, filed on 16 Dec 1991, now
patented, Pat. No. US 5225538 which is a continuation of Ser. No. US
1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964
which is a continuation-in-part of Ser. No. US 1989-315015, filed on 23
Feb 1989, now patented, Pat. No. US 5098833

DT Utility

FS Granted

LN.CNT 2630

INCL INCLM: 530/350.000

INCLS: 530/387.100; 536/023.400; 435/064.700

NCL NCLM: 530/350.000

NCLS: 435/069.700; 530/387.100; 536/023.400

IC [6]

ICM: C07K013-00

EXF 435/69.7; 435/252.3; 435/320.1; 530/350; 530/387.1; 536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 116 OF 201 USPATFULL on STN

AN 92:42890 USPATFULL

TI Hybrid immunoglobulins

IN Capon, Daniel J., San Mateo, CA, United States

Lasky, Laurence A., Sausalito, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)

PI US 5116964 19920526

AI US 1989-440625 19891122 (7)

RLI Continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989

DT Utility

FS Granted

LN.CNT 2533

INCL INCLM: 536/027.000
INCLS: 435/069.700; 435/252.300; 435/320.110; 530/350.000
NCL NCLM: 536/023.500
NCLS: 424/134.100; 435/069.700; 435/252.300; 435/320.100; 530/350.000;
530/387.300; 536/023.510; 536/023.530
IC [5]
ICM: C07H021-04
ICS: C12N015-62; C12P021-02
EXF 435/69.7; 435/172.3; 435/252.3; 435/320; 436/512; 530/350; 530/387;
536/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 117 OF 201 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1991-01425 BIOTECHDS
TI Cloned DNA comprising two parts coding for domains of CD4;
for producing a peptide for use in therapy of AIDS; chimeric antibody
construction; antibody engineering; potential application in HIV virus
inhibition
PA Roche
PI EP 394827 31 Oct 1990
AI EP 1990-107393 19 Apr 1990
PRAI EP 1989-117606 23 Sep 1989; EP 1989-107572 26 Apr 1989
DT Patent
LA English
OS WPI: 1990-328885 [44]

L4 ANSWER 118 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26332 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid peptide mutant (Abeta residues 1-40).

L4 ANSWER 119 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26331 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid peptide mutant (Abeta residues 1-29).

L4 ANSWER 120 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26330 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent

LA English
OS 2002-636427 [68]
DESC Human beta-amyloid peptide mutant (Abeta residues 10-25).

L4 ANSWER 121 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26302 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Geftter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid peptide (beta-AP) with glycine linker #2.

L4 ANSWER 122 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26301 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Geftter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid peptide (beta-AP) with glycine linker #1.

L4 ANSWER 123 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26300 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Geftter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
CR N-PSDB: AAD43954
DESC Human beta-amyloid peptide (beta-AP) #5.

L4 ANSWER 124 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26299 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Geftter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC Human tPA secretory leader peptide.

L4 ANSWER 125 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26298 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #20 capable of binding an amyloidogenic protein.

L4 ANSWER 126 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26297 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #19 capable of binding an amyloidogenic protein.

L4 ANSWER 127 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26296 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #18 capable of binding an amyloidogenic protein.

L4 ANSWER 128 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26295 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #17 capable of binding an amyloidogenic protein.

L4 ANSWER 129 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26294 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,

e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 Gefter M L; Israel D I; Joyal J L; Gosselin M
 (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Peptide #16 capable of binding an amyloidogenic protein.

L4 ANSWER 130 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE26293 peptide DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 Gefter M L; Israel D I; Joyal J L; Gosselin M
 (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Peptide #15 capable of binding an amyloidogenic protein.

L4 ANSWER 131 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE26292 peptide DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 Gefter M L; Israel D I; Joyal J L; Gosselin M
 (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Peptide #14 capable of binding an amyloidogenic protein.

L4 ANSWER 132 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE26291 peptide DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 Gefter M L; Israel D I; Joyal J L; Gosselin M
 (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Peptide #13 capable of binding an amyloidogenic protein.

L4 ANSWER 133 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE26290 peptide DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 Gefter M L; Israel D I; Joyal J L; Gosselin M

PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #12 capable of binding an amyloidogenic protein.

L4 ANSWER 134 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26289 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
(PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #11 capable of binding an amyloidogenic protein.

L4 ANSWER 135 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26288 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
(PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #10 capable of binding an amyloidogenic protein.

L4 ANSWER 136 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26286 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
(PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #9 capable of binding an amyloidogenic protein.

L4 ANSWER 137 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26284 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
(PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127

US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #8 capable of binding an amyloidogenic protein.

L4 ANSWER 138 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26283 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #7 capable of binding an amyloidogenic protein.

L4 ANSWER 139 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26282 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #6 capable of binding an amyloidogenic protein.

L4 ANSWER 140 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26281 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #5 capable of binding an amyloidogenic protein.

L4 ANSWER 141 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26279 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English

OS 2002-636427 [68]
DESC Peptide #4 capable of binding an amyloidogenic protein.

L4 ANSWER 142 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26277 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #3 capable of binding an amyloidogenic protein.

L4 ANSWER 143 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26276 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #2 capable of binding an amyloidogenic protein.

L4 ANSWER 144 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26275 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC Peptide #1 capable of binding an amyloidogenic protein.

L4 ANSWER 145 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26274 Protein DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta amyloid-IgG1 Fc fusion protein.

L4 ANSWER 146 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAE26273 Protein DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselein M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
CR N-PSDB: AAD43943
DESC Human tPA delta pro/16-30/Fc fusion protein.

L4 ANSWER 147 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26272 Protein DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselein M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human IgG1 heavy chain.

L4 ANSWER 148 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26271 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselein M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid peptide (beta-AP) #4.

L4 ANSWER 149 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26270 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselein M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human tissue plasminogen activator (tPA) signal peptide.

L4 ANSWER 150 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAE26269 peptide DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***

heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Human islet amyloid polypeptide (IAPP) peptide.

L4 ANSWER 151 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE26268 peptide DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Human amyloidogenic peptide.

L4 ANSWER 152 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE26267 peptide DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Human beta-amyloid peptide (beta-AP) #3.

L4 ANSWER 153 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE26266 peptide DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Human beta-amyloid peptide (beta-AP) #2.

L4 ANSWER 154 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE26265 peptide DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.

PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Human beta-amyloid peptide (beta-AP) #1.

L4 ANSWER 155 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAR44420 Protein DGENE
 TI New fusion proteins for treating bacterial infections - comprising a bactericidal-permeability-increasing protein and a immunoglobulin heavy chain constant domain
 IN Grinna L S; Horwitz A; Theofan G
 PA (XOMA) XOMA CORP.
 PI WO 9323434 A2 19931125 75p
 AI WO 1993-US4754 19930519
 PRAI US 1992-885911 19920519
 DT Patent
 LA English
 OS 1993-386485 [48]
 CR N-PSDB: AAQ52488
 DESC pING4512 encoded fusion protein.

L4 ANSWER 156 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAR44419 Peptide DGENE
 TI New fusion proteins for treating bacterial infections - comprising a bactericidal-permeability-increasing protein and a immunoglobulin heavy chain constant domain
 IN Grinna L S; Horwitz A; Theofan G
 PA (XOMA) XOMA CORP.
 PI WO 9323434 A2 19931125 75p
 AI WO 1993-US4754 19930519
 PRAI US 1992-885911 19920519
 DT Patent
 LA English
 OS 1993-386485 [48]
 DESC rBPI-IgG fusion N-terminal sequence.

L4 ANSWER 157 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAR44418 Peptide DGENE
 TI New fusion proteins for treating bacterial infections - comprising a bactericidal-permeability-increasing protein and a immunoglobulin heavy chain constant domain
 IN Grinna L S; Horwitz A; Theofan G
 PA (XOMA) XOMA CORP.
 PI WO 9323434 A2 19931125 75p
 AI WO 1993-US4754 19930519
 PRAI US 1992-885911 19920519
 DT Patent
 LA English
 OS 1993-386485 [48]
 DESC IgG hinge region upstream fragment.

L4 ANSWER 158 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAR44417 Peptide DGENE
 TI New fusion proteins for treating bacterial infections - comprising a bactericidal-permeability-increasing protein and a immunoglobulin heavy chain constant domain
 IN Grinna L S; Horwitz A; Theofan G
 PA (XOMA) XOMA CORP.
 PI WO 9323434 A2 19931125 75p
 AI WO 1993-US4754 19930519
 PRAI US 1992-885911 19920519
 DT Patent
 LA English
 OS 1993-386485 [48]
 DESC IgG 5' fragment.

L4 ANSWER 159 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAD43969 DNA DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder, e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked

to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M

IN (PRAE-N) PRAECIS PHARM INC.

PA WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127

US 2000-250198P 20001129

US 2000-257186P 20001220

DT Patent

LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-235.

L4 ANSWER 160 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAD43968 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked

to a peptide capable of binding amyloidogenic protein -

Gefter M L; Israel D I; Joyal J L; Gosselin M

IN (PRAE-N) PRAECIS PHARM INC.

PA WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127

US 2000-250198P 20001129

US 2000-257186P 20001220

DT Patent

LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-234-3G.

L4 ANSWER 161 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAD43967 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked

to a peptide capable of binding amyloidogenic protein -

Gefter M L; Israel D I; Joyal J L; Gosselin M

IN (PRAE-N) PRAECIS PHARM INC.

PA WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127

US 2000-250198P 20001129

US 2000-257186P 20001220

DT Patent

LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-234.

L4 ANSWER 162 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAD43966 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked

to a peptide capable of binding amyloidogenic protein -

Gefter M L; Israel D I; Joyal J L; Gosselin M

IN (PRAE-N) PRAECIS PHARM INC.

PA WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127

US 2000-250198P 20001129

US 2000-257186P 20001220

DT Patent

LA English

OS 2002-636427 [68]

DESC Human beta-amyloid gene fragment, DI-233.

L4 ANSWER 163 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AAD43965 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked

to a peptide capable of binding amyloidogenic protein -

Gefter M L; Israel D I; Joyal J L; Gosselin M

IN (PRAE-N) PRAECIS PHARM INC.

PA WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid gene fragment, DI-232-3G.

L4 ANSWER 164 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43964 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid gene fragment, DI-232.

L4 ANSWER 165 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43963 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid gene fragment, DI-231.

L4 ANSWER 166 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43962 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC DI230 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 167 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43961 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p

AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC DI229 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 168 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43960 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
(PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC DI228 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 169 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43959 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
(PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC DI227 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 170 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43958 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
(PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC DI226 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 171 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43957 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
Gefter M L; Israel D I; Joyal J L; Gosselin M
(PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220

DT Patent
LA English
OS 2002-636427 [68]
DESC DI225 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 172 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAD43956 DNA DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC DI224 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 173 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAD43955 DNA DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC DI223 oligo used to assemble beta-amyloid gene subfragment.

L4 ANSWER 174 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAD43954 DNA DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 CR P-PSDB: AAE26300
 DESC Human beta-amyloid gene.

L4 ANSWER 175 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAD43953 DNA DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Human beta-amyloid DNA fragment, DI222-4.

L4 ANSWER 176 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAD43952 DNA DGENE

TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid DNA fragment, DI222-40.

L4 ANSWER 177 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43951 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid DNA fragment, DI221.

L4 ANSWER 178 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43950 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid DNA fragment, DI220.

L4 ANSWER 179 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43949 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid DNA fragment, DI219.

L4 ANSWER 180 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43948 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -

IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid DNA fragment, DI218.

L4 ANSWER 181 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43947 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid DNA fragment, DI217-3G.

L4 ANSWER 182 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43946 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC Human beta-amyloid DNA fragment, DI217.

L4 ANSWER 183 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43945 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127
PRAI US 2000-253302P 20001127
US 2000-250198P 20001129
US 2000-257186P 20001220
DT Patent
LA English
OS 2002-636427 [68]
DESC DI216 oligo used to assemble synthetic APP/IgG gene.

L4 ANSWER 184 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAD43944 DNA DGENE
TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
e.g. Alzheimer's disease, comprises an ***immunoglobulin***
heavy ***chain*** ***constant*** ***region*** linked
to a peptide capable of binding amyloidogenic protein -
IN Gefter M L; Israel D I; Joyal J L; Gosselin M
PA (PRAE-N) PRAECIS PHARM INC.
PI WO 2002042462 A2 20020530 79p
AI WO 2001-US44581 20011127

PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC DI215 oligo used to assemble synthetic APP/IgG gene.

L4 ANSWER 185 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAD43943 DNA DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 CR P-PSDB: AAE26273
 DESC Human tPAdelta/16-30/Fc fusion DNA.

L4 ANSWER 186 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAD43942 DNA DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Mouse IgG1 fragment amplifying 3' PCR primer.

L4 ANSWER 187 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAD43941 DNA DGENE
 TI Novel therapeutic agent useful for treating an amyloidogenic disorder,
 e.g. Alzheimer's disease, comprises an ***immunoglobulin***
 heavy ***chain*** ***constant*** ***region*** linked
 to a peptide capable of binding amyloidogenic protein -
 IN Gefter M L; Israel D I; Joyal J L; Gosselin M
 PA (PRAE-N) PRAECIS PHARM INC.
 PI WO 2002042462 A2 20020530 79p
 AI WO 2001-US44581 20011127
 PRAI US 2000-253302P 20001127
 US 2000-250198P 20001129
 US 2000-257186P 20001220
 DT Patent
 LA English
 OS 2002-636427 [68]
 DESC Mouse IgG1 fragment amplifying 5' PCR primer.

L4 ANSWER 188 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAT84744 DNA DGENE
 TI Hybrid fusion protein for treating Gram-negative bacterial infections -
 comprising bactericidal/permeability increasing protein and
 immunoglobulin heavy chain constant domain
 IN Grinna L S; Horwitz A; Theofan G
 PA (XOMA) XOMA CORP.
 PI US 5643570 A 19970701 31p
 AI US 1993-64693 19930519
 PRAI US 1993-64693 19930519
 US 1992-885911 19920519
 DT Patent
 LA English

OS 1997-350186 [32]
DESC Primer BPI-2 for bactericidal permeability increasing protein DNA.

L4 ANSWER 189 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAT84743 DNA DGENE
TI Hybrid fusion protein for treating Gram-negative bacterial infections -
comprising bactericidal/permeability increasing protein and
immunoglobulin heavy chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI US 5643570 A 19970701 31p
AI US 1993-64693 19930519
PRAI US 1993-64693 19930519
US 1992-885911 19920519
DT Patent
LA English
OS 1997-350186 [32]
DESC Primer BPI-23 for bactericidal permeability increasing protein DNA.

L4 ANSWER 190 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAT84742 DNA DGENE
TI Hybrid fusion protein for treating Gram-negative bacterial infections -
comprising bactericidal/permeability increasing protein and
immunoglobulin heavy chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI US 5643570 A 19970701 31p
AI US 1993-64693 19930519
PRAI US 1993-64693 19930519
US 1992-885911 19920519
DT Patent
LA English
OS 1997-350186 [32]
DESC Primer BPI-14 for bactericidal permeability increasing protein DNA.

L4 ANSWER 191 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAT84741 DNA DGENE
TI Hybrid fusion protein for treating Gram-negative bacterial infections -
comprising bactericidal/permeability increasing protein and
immunoglobulin heavy chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI US 5643570 A 19970701 31p
AI US 1993-64693 19930519
PRAI US 1993-64693 19930519
US 1992-885911 19920519
DT Patent
LA English
OS 1997-350186 [32]
DESC Primer BPI-6 for bactericidal permeability increasing protein DNA.

L4 ANSWER 192 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAT84740 DNA DGENE
TI Hybrid fusion protein for treating Gram-negative bacterial infections -
comprising bactericidal/permeability increasing protein and
immunoglobulin heavy chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI US 5643570 A 19970701 31p
AI US 1993-64693 19930519
PRAI US 1993-64693 19930519
US 1992-885911 19920519
DT Patent
LA English
OS 1997-350186 [32]
DESC Primer BPI-11 for bactericidal permeability increasing protein DNA.

L4 ANSWER 193 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAT84739 DNA DGENE
TI Hybrid fusion protein for treating Gram-negative bacterial infections -
comprising bactericidal/permeability increasing protein and
immunoglobulin heavy chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI US 5643570 A 19970701 31p
AI US 1993-64693 19930519

PRAI US 1993-64693 19930519
US 1992-885911 19920519
DT Patent
LA English
OS 1997-350186 [32]
DESC Primer BPI-5 for bactericidal permeability increasing protein DNA.

L4 ANSWER 194 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ52488 DNA DGENE
TI New fusion proteins for treating bacterial infections - comprising a
bactericidal-permeability-increasing protein and a immunoglobulin heavy
chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI WO 9323434 A2 19931125 75p
AI WO 1993-US4754 19930519
PRAI US 1992-885911 19920519
DT Patent
LA English
OS 1993-386485 [48]
CR P-PSDB: AAR44420
DESC pING4512 coding region.

L4 ANSWER 195 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ52484 DNA DGENE
TI New fusion proteins for treating bacterial infections - comprising a
bactericidal-permeability-increasing protein and a immunoglobulin heavy
chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI WO 9323434 A2 19931125 75p
AI WO 1993-US4754 19930519
PRAI US 1992-885911 19920519
DT Patent
LA English
OS 1993-386485 [48]
DESC Primer BPI-14.

L4 ANSWER 196 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ52483 DNA DGENE
TI New fusion proteins for treating bacterial infections - comprising a
bactericidal-permeability-increasing protein and a immunoglobulin heavy
chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI WO 9323434 A2 19931125 75p
AI WO 1993-US4754 19930519
PRAI US 1992-885911 19920519
DT Patent
LA English
OS 1993-386485 [48]
DESC Primer BPI-6.

L4 ANSWER 197 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ52482 DNA DGENE
TI New fusion proteins for treating bacterial infections - comprising a
bactericidal-permeability-increasing protein and a immunoglobulin heavy
chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI WO 9323434 A2 19931125 75p
AI WO 1993-US4754 19930519
PRAI US 1992-885911 19920519
DT Patent
LA English
OS 1993-386485 [48]
DESC Primer BPI-11.5.

L4 ANSWER 198 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ52481 DNA DGENE
TI New fusion proteins for treating bacterial infections - comprising a
bactericidal-permeability-increasing protein and a immunoglobulin heavy
chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI WO 9323434 A2 19931125 75p

AI WO 1993-US4754 19930519
PRAI US 1992-885911 19920519
DT Patent
LA English
OS 1993-386485 [48]
DESC Primer BPI-5.

L4 ANSWER 199 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ52480 DNA DGENE
TI New fusion proteins for treating bacterial infections - comprising a
bactericidal-permeability-increasing protein and a immunoglobulin heavy
chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI WO 9323434 A2 19931125 75p
AI WO 1993-US4754 19930519
PRAI US 1992-885911 19920519
DT Patent
LA English
OS 1993-386485 [48]
DESC Primer CH2-2C-Dra.

L4 ANSWER 200 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ52479 DNA DGENE
TI New fusion proteins for treating bacterial infections - comprising a
bactericidal-permeability-increasing protein and a immunoglobulin heavy
chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI WO 9323434 A2 19931125 75p
AI WO 1993-US4754 19930519
PRAI US 1992-885911 19920519
DT Patent
LA English
OS 1993-386485 [48]
DESC Primer KAO-gamma3.

L4 ANSWER 201 OF 201 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAQ52478 DNA DGENE
TI New fusion proteins for treating bacterial infections - comprising a
bactericidal-permeability-increasing protein and a immunoglobulin heavy
chain constant domain
IN Grinna L S; Horwitz A; Theofan G
PA (XOMA) XOMA CORP.
PI WO 9323434 A2 19931125 75p
AI WO 1993-US4754 19930519
PRAI US 1992-885911 19920519
DT Patent
LA English
OS 1993-386485 [48]
DESC Primer CH2-Msc.

STN INTERNATIONAL LOGOFF AT 16:37:49 ON 18 NOV 2004